U.S. patent application number 16/150796 was filed with the patent office on 2019-06-06 for ccr6 compounds.
The applicant listed for this patent is CHEMOCENTRYX, INC.. Invention is credited to Daniel DAIRAGHI, Dean R. DRAGOLI, Jaroslaw KALISIAK, Christopher W. LANGE, Manmohan Reddy LELETI, Yandong LI, Rebecca M. LUI, Viengkham MALATHONG, Venkat Reddy MALI, Jay P. POWERS, Joanne TAN, Hiroko TANAKA, Matthew J. WALTERS, Ju YANG, Penglie ZHANG.
Application Number | 20190167659 16/150796 |
Document ID | / |
Family ID | 53274030 |
Filed Date | 2019-06-06 |
![](/patent/app/20190167659/US20190167659A1-20190606-C00001.png)
![](/patent/app/20190167659/US20190167659A1-20190606-C00002.png)
![](/patent/app/20190167659/US20190167659A1-20190606-C00003.png)
![](/patent/app/20190167659/US20190167659A1-20190606-C00004.png)
![](/patent/app/20190167659/US20190167659A1-20190606-C00005.png)
![](/patent/app/20190167659/US20190167659A1-20190606-C00006.png)
![](/patent/app/20190167659/US20190167659A1-20190606-C00007.png)
![](/patent/app/20190167659/US20190167659A1-20190606-C00008.png)
![](/patent/app/20190167659/US20190167659A1-20190606-C00009.png)
![](/patent/app/20190167659/US20190167659A1-20190606-C00010.png)
![](/patent/app/20190167659/US20190167659A1-20190606-C00011.png)
View All Diagrams
United States Patent
Application |
20190167659 |
Kind Code |
A1 |
DAIRAGHI; Daniel ; et
al. |
June 6, 2019 |
CCR6 COMPOUNDS
Abstract
Compounds of formula (I) are provided which are useful in the
treatment of diseases or conditions modulated at least in part by
CCR6: ##STR00001##
Inventors: |
DAIRAGHI; Daniel; (Palo
Alto, CA) ; DRAGOLI; Dean R.; (Los Altos, CA)
; KALISIAK; Jaroslaw; (Mountain View, CA) ; LANGE;
Christopher W.; (El Cerrito, CA) ; LELETI; Manmohan
Reddy; (Dublin, CA) ; LI; Yandong; (San Diego,
CA) ; LUI; Rebecca M.; (Santa Clara, CA) ;
MALI; Venkat Reddy; (Cupertino, CA) ; MALATHONG;
Viengkham; (Mountain View, CA) ; POWERS; Jay P.;
(Pacifica, CA) ; TANAKA; Hiroko; (Mountain View,
CA) ; TAN; Joanne; (San Francisco, CA) ;
WALTERS; Matthew J.; (Pacifica, CA) ; YANG; Ju;
(Palo Alto, CA) ; ZHANG; Penglie; (Foster City,
CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
CHEMOCENTRYX, INC. |
Mountain View |
CA |
US |
|
|
Family ID: |
53274030 |
Appl. No.: |
16/150796 |
Filed: |
October 3, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15709012 |
Sep 19, 2017 |
10117865 |
|
|
16150796 |
|
|
|
|
15074965 |
Mar 18, 2016 |
9795599 |
|
|
15709012 |
|
|
|
|
14557949 |
Dec 2, 2014 |
9340509 |
|
|
15074965 |
|
|
|
|
61910838 |
Dec 2, 2013 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 3/10 20180101; C07D
405/14 20130101; A61P 9/00 20180101; A61P 17/06 20180101; A61K
31/47 20130101; A61P 37/08 20180101; A61P 25/28 20180101; A61P
17/04 20180101; A61P 17/00 20180101; A61P 11/06 20180101; A61P
11/00 20180101; A61P 43/00 20180101; A61P 29/00 20180101; A61P
37/06 20180101; A61P 15/02 20180101; A61P 31/00 20180101; C07D
215/48 20130101; A61K 31/4709 20130101; C07D 405/04 20130101; A61P
9/10 20180101; A61P 11/02 20180101; A61P 1/00 20180101; A61P 5/16
20180101 |
International
Class: |
A61K 31/47 20060101
A61K031/47; A61K 31/4709 20060101 A61K031/4709; C07D 405/14
20060101 C07D405/14; C07D 215/48 20060101 C07D215/48; C07D 405/04
20060101 C07D405/04 |
Claims
1. A compound having formula (I): ##STR00030## or a
pharmaceutically acceptable salt, hydrate, solvate, N-oxide or
rotamer thereof, wherein A is a carboxylic acid moiety or a
carboxylic acid isostere; ring vertices a, b, c and d are
independently selected from N, CH and C(R.sup.1); each R.sup.1 is
independently selected from the group consisting of halogen, CN,
--SF.sub.5, C.sub.1-8 alkyl, C.sub.3-8 cycloalkyl, C.sub.2-8
alkenyl, C.sub.2-8 alkynyl, C.sub.1-8 haloalkyl, --OR.sup.a,
--SR.sup.a, --COR.sup.a, --NR.sup.aR.sup.b, and 5- or 6-membered
heteroaryl, wherein the alkyl portions of R.sup.1 are optionally
further substituted with 1-3 R.sup.a; and optionally, adjacent
R.sup.1 members are connected to form an additional 5- or
6-membered ring which is saturated or unsaturated having ring
vertices selected from C, O, S and N, wherein the additional 5- or
6-membered ring is optionally substituted with one or two members
selected from the group consisting of halogen, hydroxyl, C.sub.1-4
alkyl, C.sub.1-4 alkoxy and C.sub.1-4 haloalkyl; the subscript m is
an integer of from 0 to 2; the subscript n is an integer of from 0
to 3; each R.sup.2 and R.sup.3 is independently selected from the
group consisting of halogen, CN, C.sub.1-8 alkyl, C.sub.3-8
cycloalkyl, C.sub.2-8 alkenyl, C.sub.2-8 alkynyl, C.sub.1-8
haloalkyl, aryl, --OR.sup.a, --NR.sup.aR.sup.b and
--N(R.sup.a)--C.sub.1-C.sub.4 alkylene-OR.sup.b, and wherein the
alkyl or aryl portions of R.sup.2 and R.sup.3 are optionally
further substituted with 1-3 R.sup.a; Ar is a 5- or 6-membered
aromatic or heteroaromatic ring that is optionally substituted with
from 1 to 5 R.sup.4 substituents independently selected from the
group consisting of halogen, CN, --SF.sub.5, C.sub.1-8 alkyl,
C.sub.3-8 cycloalkyl, C.sub.2-8 alkenyl, C.sub.2-8 alkynyl,
C.sub.1-8 haloalkyl, C.sub.1-8 hydroxyalkyl, --OR.sup.a,
--NR.sup.aR.sup.b, 5- or 6-membered heteroaryl, and 3-, 4-, 5- or
6-membered heterocycloalkane wherein the heteroatoms present as
ring vertices of the heteroaryl and heterocycloalkane rings are
selected from N, O and S, and wherein the alkyl, cycloalkyl, aryl,
heteroaryl and hetereocycloalkane portions of R.sup.4 are
optionally further substituted with 1-3 R.sup.a; each R.sup.a and
R.sup.b is independently selected from the group consisting of
hydrogen, hydroxyl, halogen, cyano, C.sub.1-4 alkyl, C.sub.1-4
alkoxy, C.sub.1-4 haloalkyl, C.sub.3-6 cycloalkyl, amino, C.sub.1-8
alkylamino, and di C.sub.1-8 alkylamino, or when attached to a
nitrogen atom are optionally combined to form a 4- to 7-membered
saturated ring, which is optionally substituted with oxo.
2-18. (canceled)
19. A compound of claim 1, wherein Ar is selected from the group
consisting of: ##STR00031## wherein the wavy line labeled w
indicates the point of attachment to the S(O).sub.2 moiety.
20. A compound of claim 1, selected from the group consisting of:
##STR00032## ##STR00033## ##STR00034##
21. A compound of claim 1, selected from the group consisting of:
##STR00035## or a pharmaceutically acceptable salt, hydrate,
solvate, N-oxide or rotamer thereof.
22. A pharmaceutical composition comprising a compound of claim 1,
or a pharmaceutically acceptable salt, hydrate, solvate, N-oxide or
rotamer thereof, with a pharmaceutically acceptable excipient.
23. A method of treating a disease or condition modulated at least
in part by CCR6, comprising administering to a subject in need
thereof, a compound of claim 1, or a pharmaceutically acceptable
salt, hydrate, solvate, N-oxide or rotamer thereof.
24. A method in accordance with claim 23, wherein said disease or
condition is an inflammatory disease or condition.
25. A method in accordance with claim 23, wherein said disease or
condition is atopic dermatitis.
26. A method in accordance with claim 23, wherein said disease or
condition is psoriasis.
27. A method of treating a disease or condition modulated at least
in part by CCR6, comprising administering to a subject in need
thereof, a compound of claim 19, or a pharmaceutically acceptable
salt, hydrate, solvate, N-oxide or rotamer thereof.
28. A method in accordance with claim 27, wherein the compound is
selected from the group consisting of: ##STR00036## ##STR00037##
##STR00038## or a pharmaceutically acceptable salt, hydrate,
solvate, N-oxide or rotamer thereof.
29. A method in accordance with claim 27, wherein the compound is
selected from the group consisting of: ##STR00039## or a
pharmaceutically acceptable salt, hydrate, solvate, N-oxide or
rotamer thereof.
Description
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 15/709,012, filed Sep. 19, 2017, which is a
continuation of U.S. patent application Ser. No. 15/074,965, filed
Mar. 18, 2016 (now U.S. Pat. No. 9,795,599), which is a
continuation of U.S. patent application Ser. No. 14/557,949, filed
Dec. 2, 2014 (now U.S. Pat. No. 9,340,509), which claims the
benefit of priority to U.S. Patent Application No. 61/910,838,
filed Dec. 2, 2013, the disclosures of which are herein
incorporated by reference in their entirety.
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED
RESEARCH AND DEVELOPMENT
[0002] Not Applicable
REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM
LISTING APPENDIX SUBMITTED ON AS AN ASCII TEXT FILE
[0003] The Sequence Listing written in file-102-1.TXT, created on
Jan. 5, 2015, 16,384 bytes, machine format IBM-PC, MS-Windows
operating system, is hereby incorporated by reference in its
entirety for all purposes.
BACKGROUND OF THE INVENTION
[0004] Chemokines are chemotactic cytokines that are released by a
wide variety of cells to attract macrophages, T cells, eosinophils,
basophils and neutrophils to sites of inflammation (reviewed in
Schall, Cytokine, 3:165-183 (1991), Schall, et al., Curr Opin.
Immunol. 6:865-873 (1994) and Murphy, Rev. Immun., 12:593-633
(1994)). In addition to stimulating chemotaxis, other changes can
be selectively induced by chemokines in responsive cells, including
changes in cell shape, transient rises in the concentration of
intracellular free calcium ions ([Ca2+]), granule exocytosis,
integrin upregulation, formation of bioactive lipids (e.g.,
leukotrienes) and respiratory burst, associated with leukocyte
activation. Thus, the chemokines are early triggers of the
inflammatory response, causing inflammatory mediator release,
chemotaxis and extravasation to sites of infection or
inflammation.
[0005] There are two main classes of chemokines, CXC (alpha) and CC
(beta), depending on whether the first two cysteines are separated
by a single amino acid (C--X--C) or are adjacent (C--C). The
alpha-chemokines, such as interleukin-8 (IL-8),
neutrophil-activating protein-2 (NAP-2) and melanoma growth
stimulatory activity protein (MGSA) are chemotactic primarily for
neutrophils, whereas beta-chemokines, such as RANTES, MIP-1a,
MIP-1b, monocyte chemotactic protein-1 (MCP-1), MCP-2, MCP-3 and
eotaxin are chemotactic for macrophages, T-cells, eosinophils and
basophils (Deng, et al., Nature, 381:661-666 (1996)). The
chemokines bind specific cell-surface receptors belonging to the
family of G-protein-coupled seven-transmembrane-domain proteins
(reviewed in Horuk, Trends Pharm. Sci., 15:159-165 (1994)) which
are termed "chemokine receptors."
[0006] On binding their cognate ligands, chemokine receptors
transduce an intracellular signal though the associated trimeric G
protein, resulting in a rapid increase in intracellular calcium
concentration. There are at least eleven human chemokine receptors
that bind or respond to beta-chemokines and at least seven human
chemokine recepotrs that bind to the alpha chemokines. Additionally
CX3CR1 (fractalkine receptor) can bind to the fractalkine
chemokine, which is distinguished by a series of three amino acids
between the first two cysteines. Chemokine receptors, have been
implicated as being important mediators of inflammatory and
immunoregulatory disorders and diseases, including asthma and
allergic diseases, as well as autoimmune pathologies such as
rheumatoid arthritis and atherosclerosis.
[0007] CCR6 is known to be expressed primarily in B cells, IL17
secreting T cells, regulatory T cells and dendritic cells and shows
strong binding to its cognate ligand CCL20 (MIP-3a). It is
expressed on approximately 30-60% of adult peripheral blood
effector/memory CD4+ T cells. CCR6 is involved in leukocyte homing
to inflamed tissue, particularly the skin and lungs and is
co-expressed on almost all T cells that have a skin homing
phenotype, the CLA+ T cells. Thus CCR6 may be an important player
in skin pathologies in which leukocytes participate.
[0008] CCR6 expression has been linked to psoriasis in the
following manner. In humans, a large majority of skin-homing CD4 T
cells in the peripheral blood express CCR6 with a greater degree of
CCL20-mediated chemotaxis occurring in T cells isolated from
psoriatic patients (Homey, et. al., JI, 2000). IL17 secreting cells
are central agents in several inflammatory diseases. T cells, such
as .gamma..delta. T cells and TH17 T cells produce IL17 after
activation. The pathogenic effects of IL17 have been associated
with human diseases such as rheumatoid arthritis (Patel D D et.
al., Ann Rheum Dis 2013), multiple sclerosis (Zepp J, Wu L, and X
Li Trends Immunol 2011), and psoriasis (Martin D A et. al., J
Invest Dermatol 2012). Evidence strongly linking IL17 with
psoriasis include gene wide association studies that show strong
association between psoriasis and genes upstream (IL-23) or
downstream (NF.kappa.b) of IL17 signaling pathways as well as
efficacy in targeting IL17 in a clinical setting (Martin D A et.
al., J. Invest Dermat. 2012; Papp et. al., NEJM, 2012; Papp et.
al., NEJM, 2012). In addition to enhanced CCL20-mediated
chemotaxis, CCR6+ T cells isolated from psoriatic patients
preferentially secrete IL-17A, IL22, and TNF.alpha. when compared
to healthy controls (Kagami, et. al., J. Invest. Dermatol., 2010).
Lastly, cc120 mRNA was up-regulated in lesional psoriatic skin
samples (Homey, et. al., JI, 2000; Dieu-Nosjean, et. al., JEM,
2000). In mice, CCR6 knock-out mice were protected from IL-23
driven psoriasis. Thus, a multitude of evidence in both mice and
men suggest a protective role for CCR6 blockade in psoriasis and
psoriasis-like models.
[0009] In view of the clinical importance of CCR6, the
identification of compounds that modulate CCR6 function represent
an attractive avenue into the development of new therapeutic
agents. Such compounds and methods for their use are provided
herein.
BRIEF SUMMARY OF THE INVENTION
[0010] Described herein are compounds having formula (I):
##STR00002##
wherein the ring vertices a, b, c and d; Ar; A; R.sup.2, R.sup.3
and the subscripts m and n have the meanings provided in the
Detailed Description below. The compounds have utility in the
treatment of diseases or conditions modulated at least in part by
CCR6.
[0011] Pharmaceutical compositions of the compounds of formula (I)
are also provided.
[0012] Further provided in the present disclosure preparative
methods for the synthesis of compounds of formula (I), as well as
selected intermediates useful in the preparation.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIGS. 1A-1H provide structures and binding data for
compounds prepared and evaluated by the methods described herein.
Activity is shown as +, 20000 nM.gtoreq.IC.sub.50.gtoreq.500 nM;
++, 500 nM>IC.sub.50.gtoreq.100 nM; +++, 100
nM>IC.sub.50.
[0014] FIGS. 2A-2C provide structures and migration data for
compounds prepared and evaluated by the methods described herein.
Activity is shown as +, 20000 nM.gtoreq.IC50.gtoreq.500 nM; ++, 500
nM>IC50.gtoreq.100 nM; +++, 100 nM>IC.sub.50.
DETAILED DESCRIPTION OF THE INVENTION
I. Abbreviation and Definitions
[0015] The term "alkyl", by itself or as part of another
substituent, means, unless otherwise stated, a straight or branched
chain hydrocarbon radical, having the number of carbon atoms
designated (i.e. C.sub.1-8 means one to eight carbons). Examples of
alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl,
t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl,
and the like. The term "alkenyl" refers to an unsaturated alkyl
group having one or more double bonds. Similarly, the term
"alkynyl" refers to an unsaturated alkyl group having one or more
triple bonds. Examples of such unsaturated alkyl groups include
vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl),
2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl,
3-butynyl, and the higher homologs and isomers. The term
"cycloalkyl" refers to hydrocarbon rings having the indicated
number of ring atoms (e.g., C.sub.3-6cycloalkyl) and being fully
saturated or having no more than one double bond between ring
vertices. "Cycloalkyl" is also meant to refer to bicyclic and
polycyclic hydrocarbon rings such as, for example,
bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, etc. The term
"heterocycloalkane" or "heterocycloalkyl" refers to a cycloalkyl
group that contain from one to five heteroatoms selected from N, O,
and S, wherein the nitrogen and sulfur atoms are optionally
oxidized, and the nitrogen atom(s) are optionally quaternized. The
heterocycloalkane may be a monocyclic, a bicyclic or a polycylic
ring system. Non limiting examples of heterocycloalkane groups
include pyrrolidine, imidazolidine, pyrazolidine, butyrolactam,
valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide,
piperidine, 1,4-dioxane, morpholine, thiomorpholine,
thiomorpholine-S-oxide, thiomorpholine-S,S-oxide, piperazine,
pyran, pyridone, 3-pyrroline, thiopyran, pyrone, tetrahydrofuran,
tetrhydrothiophene, quinuclidine, and the like. A heterocycloalkane
group can be attached to the remainder of the molecule through a
ring carbon or a heteroatom.
[0016] The term "alkylene" by itself or as part of another
substituent means a divalent radical derived from an alkane, as
exemplified by --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--. Typically, an
alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with
those groups having 10 or fewer carbon atoms being preferred in the
present invention. A "lower alkyl" or "lower alkylene" is a shorter
chain alkyl or alkylene group, generally having four or fewer
carbon atoms. Similarly, "alkenylene" and "alkynylene" refer to the
unsaturated forms of "alkylene" having double or triple bonds,
respectively.
[0017] As used herein, a wavy line, "", that intersects a single,
double or triple bond in any chemical structure depicted herein,
represent the point attachment of the single, double, or triple
bond to the remainder of the molecule.
[0018] The terms "alkoxy," "alkylamino" and "alkylthio" (or
thioalkoxy) are used in their conventional sense, and refer to
those alkyl groups attached to the remainder of the molecule via an
oxygen atom, an amino group, or a sulfur atom, respectively.
Additionally, for dialkylamino groups, the alkyl portions can be
the same or different and can also be combined to form a 3-7
membered ring with the nitrogen atom to which each is attached.
Accordingly, a group represented as dialkylamino or
--NR.sup.aR.sup.b is meant to include piperidinyl, pyrrolidinyl,
morpholinyl, azetidinyl and the like.
[0019] The term "di-(C.sub.1-4alkyl)amino-C.sub.1-4 alkyl" refers
to an amino group bearing two C.sub.1-4 alkyl groups that can be
the same or different (e.g., methyl, ethyl, propyl, isopropyl,
n-butyl, sec-butyl, isobutyl and tert-butyl) and which is attached
to the remainder of the molecule through a C.sub.1-4 alkyl group (a
one to four carbon alkylene linking group). Examples of
di-(C.sub.1-4 alkyl)amino-C.sub.1-4 alkyl groups include
dimethylaminomethyl, 2-(ethyl(methyl)amino)ethyl,
3-(dimethylamino)butyl, and the like.
[0020] The terms "halo" or "halogen," by themselves or as part of
another substituent, mean, unless otherwise stated, a fluorine,
chlorine, bromine, or iodine atom. Additionally, terms such as
"haloalkyl," are meant to include monohaloalkyl and polyhaloalkyl.
For example, the term "C.sub.1-4 haloalkyl" is mean to include
trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl,
3-bromopropyl, and the like.
[0021] The term "aryl" means, unless otherwise stated, a
polyunsaturated, typically aromatic, hydrocarbon group which can be
a single ring or multiple rings (up to three rings) which are fused
together or linked covalently. The term "heteroaryl" refers to aryl
groups (or rings) that contain from one to five heteroatoms
selected from N, O, and S, wherein the nitrogen and sulfur atoms
are optionally oxidized, and the nitrogen atom(s) are optionally
quaternized. A heteroaryl group can be attached to the remainder of
the molecule through a heteroatom. Non-limiting examples of aryl
groups include phenyl, naphthyl and biphenyl, while non-limiting
examples of heteroaryl groups include pyridyl, pyridazinyl,
pyrazinyl, pyrimindinyl, triazinyl, quinolinyl, quinoxalinyl,
quinazolinyl, cinnolinyl, phthalazinyl, benzotriazinyl, purinyl,
benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl,
isobenzofuryl, isoindolyl, indolizinyl, benzotriazinyl,
thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl,
imidazopyridines, benzothiaxolyl, benzofuranyl, benzothienyl,
indolyl, quinolyl, isoquinolyl, isothiazolyl, pyrazolyl, indazolyl,
pteridinyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl,
isoxazolyl, thiadiazolyl, pyrrolyl, thiazolyl, furyl, thienyl and
the like. Substituents for each of the above noted aryl and
heteroaryl ring systems are selected from the group of acceptable
substituents described below.
[0022] The term "arylalkyl" is meant to include those radicals in
which an aryl group is attached to an alkyl group (e.g., benzyl,
phenethyl, and the like). Similarly, the term "heteroaryl-alkyl" is
meant to include those radicals in which a heteroaryl group is
attached to an alkyl group (e.g., pyridylmethyl, thiazolylethyl,
and the like).
[0023] As used herein, the term "heteroatom" is meant to include
oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).
[0024] The term "pharmaceutically acceptable salts" is meant to
include salts of the active compounds which are prepared with
relatively nontoxic acids or bases, depending on the particular
substituents found on the compounds described herein. When
compounds of the present invention contain relatively acidic
functionalities, base addition salts can be obtained by contacting
the neutral form of such compounds with a sufficient amount of the
desired base, either neat or in a suitable inert solvent. Examples
of salts derived from pharmaceutically-acceptable inorganic bases
include aluminum, ammonium, calcium, copper, ferric, ferrous,
lithium, magnesium, manganic, manganous, potassium, sodium, zinc
and the like. Salts derived from pharmaceutically-acceptable
organic bases include salts of primary, secondary and tertiary
amines, including substituted amines, cyclic amines,
naturally-occuring amines and the like, such as arginine, betaine,
caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine,
2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine,
ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine,
glucosamine, histidine, hydrabamine, isopropylamine, lysine,
methylglucamine, morpholine, piperazine, piperidine, polyamine
resins, procaine, purines, theobromine, triethylamine,
trimethylamine, tripropylamine, tromethamine and the like. When
compounds of the present invention contain relatively basic
functionalities, acid addition salts can be obtained by contacting
the neutral form of such compounds with a sufficient amount of the
desired acid, either neat or in a suitable inert solvent. Examples
of pharmaceutically acceptable acid addition salts include those
derived from inorganic acids like hydrochloric, hydrobromic,
nitric, carbonic, monohydrogencarbonic, phosphoric,
monohydrogenphosphoric, dihydrogenphosphoric, sulfuric,
monohydrogensulfuric, hydriodic, or phosphorous acids and the like,
as well as the salts derived from relatively nontoxic organic acids
like acetic, propionic, isobutyric, malonic, benzoic, succinic,
suberic, fumaric, mandelic, phthalic, benzenesulfonic,
p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
Also included are salts of amino acids such as arginate and the
like, and salts of organic acids like glucuronic or galactunoric
acids and the like (see, for example, Berge, S. M., et al,
"Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977,
66, 1-19). Certain specific compounds of the present invention
contain both basic and acidic functionalities that allow the
compounds to be converted into either base or acid addition
salts.
[0025] The neutral forms of the compounds may be regenerated by
contacting the salt with a base or acid and isolating the parent
compound in the conventional manner. The parent form of the
compound differs from the various salt forms in certain physical
properties, such as solubility in polar solvents, but otherwise the
salts are equivalent to the parent form of the compound for the
purposes of the present invention.
[0026] In addition to salt forms, the present invention provides
compounds which are in a prodrug form. Prodrugs of the compounds
described herein are those compounds that readily undergo chemical
changes under physiological conditions to provide the compounds of
the present invention. Additionally, prodrugs can be converted to
the compounds of the present invention by chemical or biochemical
methods in an ex vivo environment. For example, prodrugs can be
slowly converted to the compounds of the present invention when
placed in a transdermal patch reservoir with a suitable enzyme or
chemical reagent.
[0027] Certain compounds of the present invention can exist in
unsolvated forms as well as solvated forms, including hydrated
forms. In general, the solvated forms are equivalent to unsolvated
forms and are intended to be encompassed within the scope of the
present invention. Certain compounds of the present invention may
exist in multiple crystalline or amorphous forms. In general, all
physical forms are equivalent for the uses contemplated by the
present invention and are intended to be within the scope of the
present invention.
[0028] Certain compounds of the present invention possess
asymmetric carbon atoms (optical centers) or double bonds; the
racemates, diastereomers, geometric isomers, regioisomers and
individual isomers (e.g., separate enantiomers) are all intended to
be encompassed within the scope of the present invention. The
compounds of the present invention may also contain unnatural
proportions of atomic isotopes at one or more of the atoms that
constitute such compounds. Unnatural proportions of an isotope may
be defined as ranging from the amount found in nature to an amount
consisting of 100% of the atom in question. For example, the
compounds may incorporate radioactive isotopes, such as for example
tritium (.sup.3H), iodine-125 (.sup.125I) or carbon-14 (.sup.14C),
or non-radioactive isotopes, such as deuterium (.sup.2H) or
carbon-13 (.sup.13C). Such isotopic variations can provide
additional utilities to those described elsewhere with this
application. For instance, isotopic variants of the compounds of
the invention may find additional utility, including but not
limited to, as diagnostic and/or imaging reagents, or as
cytotoxic/radiotoxic therapeutic agents. Additionally, isotopic
variants of the compounds of the invention can have altered
pharmacokinetic and pharmacodynamic characteristics which can
contribute to enhanced safety, tolerability or efficacy during
treatment. All isotopic variations of the compounds of the present
invention, whether radioactive or not, are intended to be
encompassed within the scope of the present invention.
[0029] The term "and acid isosteres" means, unless otherwise
stated, a group which can replace a carboxylic acid, having an
acidic functionality and steric and electronic characteristics that
provide a level of activity (or other compound characteristic such
as solubility) similar to a carboxylic acid. Representative acid
isosteres include, hydroxamic acids, sulfonic acids, sulfinic
acids, sulfonamides, acyl-sulfonamides, phosphonic acids,
phosphinic acids, phosphoric acids, tetrazole, and
oxo-oxadiazoles.
[0030] Compounds of the invention having formula I can exist in
different isomeric forms. As used herein, the terms cis or trans
are used in their conventional sense in the chemical arts, i.e.,
referring to the position of the substituents to one another
relative to a reference plane, e.g., a double bond, or a ring
system, such as a decalin-type ring system or a hydroquinolone ring
system: in the cis isomer, the substituents are on the same side of
the reference plane, in the trans isomer the substituents are on
opposite sides. Additionally, different conformers are contemplated
by the present invention, as well as distinct rotamers. Conformers
are conformational isomers that can differ by rotations about one
or more a bonds. Rotamers are conformers that differ by rotation
about only a single a bond.
II. General
[0031] The present invention derives from the discovery that
compounds of formula I act as potent antagonists of the CCR6
receptor. The compounds have in vivo anti-inflammatory activity and
have superior pharmacokinetic properties. Accordingly, the
compounds provided herein are useful in pharmaceutical
compositions, methods for the treatment of CCR6-mediated diseases,
and as controls in assays for the identification of competitive
CCR6 antagonists.
III. Compounds
[0032] In one aspect, the present invention provides for a compound
of Formula I:
##STR00003##
or a pharmaceutically acceptable salt, hydrate, solvate, N-oxide or
rotamer thereof. In Formula (I), the letter A represents a
carboxylic acid moiety or a carboxylic acid isostere; ring vertices
a, b, c and d are independently selected from the group consisting
of N, CH and C(R.sup.1); each R.sup.1 is independently selected
from the group consisting of halogen, CN, --SF.sub.5, C.sub.1-8
alkyl, C.sub.3-8 cycloalkyl, C.sub.2-8 alkenyl, C.sub.2-8 alkynyl,
C.sub.1-8 haloalkyl, --OR.sup.a, --SR.sup.a, --COR.sup.a,
--NR.sup.aR.sup.b, and 5- or 6-membered heteroaryl, wherein the
alkyl portions of R.sup.1 are optionally further substituted with
1-3 R.sup.a; and optionally, adjacent R.sup.1 members are connected
to form an additional 5- or 6-membered ring which is saturated or
unsaturated having ring vertices selected from C, O, S and N,
wherein the additional 5- or 6-membered ring is optionally
substituted with one or two members selected from the group
consisting of halogen, hydroxyl, C.sub.1-4 alkyl, C.sub.1-4 alkoxy
and C.sub.1-4 haloalkyl; the subscript m is an integer of from 0 to
2; the subscript n is an integer of from 0 to 3; each R.sup.2 and
R.sup.3 is independently selected from the group consisting of
halogen, CN, C.sub.1-8 alkyl, C.sub.3-8 cycloalkyl, C.sub.2-8
alkenyl, C.sub.2-8 alkynyl, C.sub.1-8 haloalkyl, aryl, --OR.sup.a,
--NR.sup.aR.sup.b and --N(R.sup.a)--C.sub.1-C.sub.4
alkylene-OR.sup.b, and wherein the alkyl or aryl portions of
R.sup.2 and R.sup.3 are optionally further substituted with 1-3
R.sup.a; Ar is a 5- or 6-membered aromatic or heteroaromatic ring
that is optionally substituted with from 1 to 5 R.sup.4
substitutents independently selected from the group consisting of
halogen, CN, --SF.sub.5, C.sub.1-8 alkyl, C.sub.3-8 cycloalkyl,
C.sub.2-8 alkenyl, C.sub.2-8 alkynyl, C.sub.1-8 haloalkyl,
C.sub.1-8 hydroxyalkyl, --OR.sup.a, --NR.sup.aR.sup.b, 5- or
6-membered heteroaryl, and 3-, 4-, 5- or 6-membered
heterocycloalkane wherein the heteroatoms present as ring vertices
of the heteroaryl and heterocycloalkane rings are selected from N,
O and S, and wherein the alkyl, cycloalkyl, aryl, heteroaryl and
hetereocycloalkane portions of R.sup.4 are optionally further
substituted with 1-3 R.sup.a; each R.sup.a and R.sup.b is
independently selected from the group consisting of hydrogen,
hydroxyl, halogen, cyano, C.sub.1-4 alkyl, C.sub.1-4 alkoxy,
C.sub.1-4 haloalkyl, C.sub.3-6 cycloalkyl, amino, C.sub.1-8
alkylamino, and di C.sub.1-8 alkylamino, or when attached to a
nitrogen atom are optionally combined to form a 4- to 7-membered
saturated ring, which is optionally substituted with oxo.
[0033] In some selected embodiments, the compounds of formula (I)
are those wherein ring vertices a, b, c and d are each
independently selected from the group consisting of CH and
C(R.sup.1). In other selected embodiments, the compounds of formula
(I) are those wherein ring vertex d is CH. In still other selected
embodiments, the compounds of formula (I) are those wherein ring
vertices c and d are each CH. In yet other selected embodiments,
the compounds of formula (I) are those wherein ring vertices a, b,
and c are each C(R.sup.1). In other selected embodiments, the
compounds of formula (I) are those wherein ring vertices a and b
are each C(R.sup.1).
[0034] In the compounds of formula (I), the letter A represents a
carboxylic acid or a carboxylic acid isostere (or a suitable salt
thereof). In certain selected embodiments of formula (I), the
letter A represents a member selected from the group consisting of
--CO.sub.2H, --SO.sub.3H, --PO.sub.3H.sub.2 and a tetrazole. In
other selected embodiments, the compounds of formula (I) are those
wherein A is a carboxylic acid (--CO.sub.2H) or a tetrazole. In
some embodiments A is a tetrazole. In some embodiments, A is
--CO.sub.2H or a salt thereof.
[0035] Turning next to the substituents on the quinoline moiety, in
certain selected embodiments m and n are both 0. In other selected
embodiments, the compounds of formula (I) are those wherein m and n
are independently selected from 0 and 1. For those embodiments
wherein R.sup.2 and R.sup.3 are present, selected embodiments are
those wherein each is independently selected from the group
consisting of halogen, C.sub.1-8 alkyl, --OR.sup.a,
--NR.sup.aR.sup.b and --N(R.sup.a)--C.sub.1-C.sub.4
alkylene-OR.sup.b, and wherein the alkyl portions of R.sup.2 and
R.sup.3 are optionally further substituted with 1-3 R.sup.a.
[0036] In other selected embodiments for the compounds of formula
(I), and for each of noted embodiments above, Ar is a 6-membered
aromatic or heteroaromatic ring selected from the group consisting
of benzene, pyridine and pyrimidine, each of which is optionally
substituted with from 1-3 R.sup.4 substituents. In still other
selected embodiments for the compounds of formula (I), and for each
of noted embodiments above, Ar is selected from the group
consisting of benzene and pyridine, each of which is optionally
substituted with from 1-2 R.sup.4 substituents.
[0037] In one selected group of embodiments of formula (I), Ar is a
benzene ring which is optionally substituted with from 1-3 R.sup.4
substituents; A is --CO.sub.2H; d is CH; and each of a, b and c is
independently selected from the group consisting of CH and C(R').
In this group of embodiments, further selected embodiments are
those wherein m and n are each independently 0 or 1. Still further
selected embodiments are those wherein m and n are each 0.
[0038] In other selected embodiments for the compounds of formula
(I), and for each of noted embodiments above, the ring having a, b,
c and d as ring vertices is selected from the group consisting
of:
##STR00004##
wherein the wavy line labeled y indicates the point of attachment
to the NHS(O).sub.2 portion of the compound and the wavy line
labeled z indicates the point of attachment to the quinoline
ring.
[0039] In other selected embodiments for the compounds of formula
(I), and for each of noted embodiments above, Ar is selected from
the group consisting of:
##STR00005##
wherein the wavy line labeled w indicates the point of attachment
to the S(O).sub.2 moiety.
[0040] In still other selected embodiments, the compounds of
formula (I) are selected from the group consisting of:
##STR00006## ##STR00007## ##STR00008##
[0041] In still other selected embodiments, the compounds of
formula (I) are selected from the group consisting of:
##STR00009##
or a pharmaceutically acceptable salt, hydrate, solvate, N-oxide or
rotamer thereof.
Preparation of Compounds
[0042] The schemes in the Examples below provide certain synthetic
routes that can be followed to access certain compounds of the
present invention. Other routes or modification of the routes
presented below would be readily apparent to a skilled artisan and
are within the scope of the present invention.
IV. Pharmaceutical Compositions
[0043] In addition the compounds provided above, the compositions
for modulating CCR6, activity in humans and animals will typically
contain a pharmaceutical carrier or diluent.
[0044] The term "composition" as used herein is intended to
encompass a product comprising the specified ingredients in the
specified amounts, as well as any product which results, directly
or indirectly, from combination of the specified ingredients in the
specified amounts. By "pharmaceutically acceptable" it is meant the
carrier, diluent or excipient must be compatible with the other
ingredients of the formulation and not deleterious to the recipient
thereof.
[0045] The pharmaceutical compositions for the administration of
the compounds of this invention may conveniently be presented in
unit dosage form and may be prepared by any of the methods well
known in the art of pharmacy and drug delivery. All methods include
the step of bringing the active ingredient into association with
the carrier which constitutes one or more accessory ingredients. In
general, the pharmaceutical compositions are prepared by uniformly
and intimately bringing the active ingredient into association with
a liquid carrier or a finely divided solid carrier or both, and
then, if necessary, shaping the product into the desired
formulation. In the pharmaceutical composition the active object
compound is included in an amount sufficient to produce the desired
effect upon the process or condition of diseases.
[0046] The pharmaceutical compositions containing the active
ingredient may be in a form suitable for oral use, for example, as
tablets, troches, lozenges, aqueous or oily suspensions,
dispersible powders or granules, emulsions and self emulsifications
as described in U.S. Pat. No. 6,451,339, hard or soft capsules,
syrups, elixirs, solutions, buccal patch, oral gel, chewing gum,
chewable tablets, effervescent powder and effervescent tablets.
Compositions intended for oral use may be prepared according to any
method known to the art for the manufacture of pharmaceutical
compositions and such compositions may contain one or more agents
selected from the group consisting of sweetening agents, flavoring
agents, coloring agents, antioxidants and preserving agents in
order to provide pharmaceutically elegant and palatable
preparations. Tablets contain the active ingredient in admixture
with non-toxic pharmaceutically acceptable excipients which are
suitable for the manufacture of tablets. These excipients may be
for example, inert diluents, such as cellulose, silicon dioxide,
aluminum oxide, calcium carbonate, sodium carbonate, glucose,
mannitol, sorbitol, lactose, calcium phosphate or sodium phosphate;
granulating and disintegrating agents, for example, corn starch, or
alginic acid; binding agents, for example PVP, cellulose, PEG,
starch, gelatin or acacia, and lubricating agents, for example
magnesium stearate, stearic acid or talc. The tablets may be
uncoated or they may be coated, enterically or otherwise, by known
techniques to delay disintegration and absorption in the
gastrointestinal tract and thereby provide a sustained action over
a longer period. For example, a time delay material such as
glyceryl monostearate or glyceryl distearate may be employed. They
may also be coated by the techniques described in the U.S. Pat.
Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic
therapeutic tablets for control release.
[0047] Formulations for oral use may also be presented as hard
gelatin capsules wherein the active ingredient is mixed with an
inert solid diluent, for example, calcium carbonate, calcium
phosphate or kaolin, or as soft gelatin capsules wherein the active
ingredient is mixed with water or an oil medium, for example peanut
oil, liquid paraffin, or olive oil. Additionally, emulsions can be
prepared with a non-water miscible ingredient such as oils and
stabilized with surfactants such as mono-diglycerides, PEG esters
and the like.
[0048] Aqueous suspensions contain the active materials in
admixture with excipients suitable for the manufacture of aqueous
suspensions. Such excipients are suspending agents, for example
sodium carboxymethylcellulose, methylcellulose,
hydroxy-propylmethylcellulose, sodium alginate,
polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or
wetting agents may be a naturally-occurring phosphatide, for
example lecithin, or condensation products of an alkylene oxide
with fatty acids, for example polyoxy-ethylene stearate, or
condensation products of ethylene oxide with long chain aliphatic
alcohols, for example heptadecaethyleneoxycetanol, or condensation
products of ethylene oxide with partial esters derived from fatty
acids and a hexitol such as polyoxyethylene sorbitol monooleate, or
condensation products of ethylene oxide with partial esters derived
from fatty acids and hexitol anhydrides, for example polyethylene
sorbitan monooleate. The aqueous suspensions may also contain one
or more preservatives, for example ethyl, or n-propyl,
p-hydroxybenzoate, one or more coloring agents, one or more
flavoring agents, and one or more sweetening agents, such as
sucrose or saccharin.
[0049] Oily suspensions may be formulated by suspending the active
ingredient in a vegetable oil, for example arachis oil, olive oil,
sesame oil or coconut oil, or in a mineral oil such as liquid
paraffin. The oily suspensions may contain a thickening agent, for
example beeswax, hard paraffin or cetyl alcohol. Sweetening agents
such as those set forth above, and flavoring agents may be added to
provide a palatable oral preparation. These compositions may be
preserved by the addition of an anti-oxidant such as ascorbic
acid.
[0050] Dispersible powders and granules suitable for preparation of
an aqueous suspension by the addition of water provide the active
ingredient in admixture with a dispersing or wetting agent,
suspending agent and one or more preservatives. Suitable dispersing
or wetting agents and suspending agents are exemplified by those
already mentioned above. Additional excipients, for example
sweetening, flavoring and coloring agents, may also be present.
[0051] The pharmaceutical compositions of the invention may also be
in the form of oil-in-water emulsions. The oily phase may be a
vegetable oil, for example olive oil or arachis oil, or a mineral
oil, for example liquid paraffin or mixtures of these. Suitable
emulsifying agents may be naturally-occurring gums, for example gum
acacia or gum tragacanth, naturally-occurring phosphatides, for
example soy bean, lecithin, and esters or partial esters derived
from fatty acids and hexitol anhydrides, for example sorbitan
monooleate, and condensation products of the said partial esters
with ethylene oxide, for example polyoxyethylene sorbitan
monooleate. The emulsions may also contain sweetening and flavoring
agents.
[0052] Syrups and elixirs may be formulated with sweetening agents,
for example glycerol, propylene glycol, sorbitol or sucrose. Such
formulations may also contain a demulcent, a preservative and
flavoring and coloring agents. Oral solutions can be prepared in
combination with, for example, cyclodextrin, PEG and
surfactants.
[0053] The pharmaceutical compositions may be in the form of a
sterile injectable aqueous or oleagenous suspension. This
suspension may be formulated according to the known art using those
suitable dispersing or wetting agents and suspending agents which
have been mentioned above. The sterile injectable preparation may
also be a sterile injectable solution or suspension in a non-toxic
parenterally-acceptable diluent or solvent, for example as a
solution in 1,3-butane diol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution and
isotonic sodium chloride solution. In addition, sterile, fixed oils
are conventionally employed as a solvent or suspending medium. For
this purpose any bland fixed oil may be employed including
synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid find use in the preparation of injectables.
[0054] The compounds of the present invention may also be
administered in the form of suppositories for rectal administration
of the drug. These compositions can be prepared by mixing the drug
with a suitable non-irritating excipient which is solid at ordinary
temperatures but liquid at the rectal temperature and will
therefore melt in the rectum to release the drug. Such materials
include cocoa butter and polyethylene glycols. Additionally, the
compounds can be administered via ocular delivery by means of
solutions or ointments. Still further, transdermal delivery of the
subject compounds can be accomplished by means of iontophoretic
patches and the like. For topical use, creams, ointments, jellies,
solutions or suspensions, etc., containing the compounds of the
present invention are employed. As used herein, topical application
is also meant to include the use of mouth washes and gargles.
[0055] The compounds of the invention may be formulated for
depositing into a medical device, which may include any of variety
of conventional grafts, stents, including stent grafts, catheters,
balloons, baskets or other device that can be deployed or
permanently implanted within a body lumen. As a particular example,
it would be desirable to have devices and methods which can deliver
compounds of the invention to the region of a body which has been
treated by interventional technique.
[0056] In exemplary embodiment, the inhibitory agent of this
invention may be deposited within a medical device, such as a
stent, and delivered to the treatment site for treatment of a
portion of the body.
[0057] Stents have been used as delivery vehicles for therapeutic
agents (i.e., drugs). Intravascular stents are generally
permanently implanted in coronary or peripheral vessels. Stent
designs include those of U.S. Pat. No. 4,733,655 (Palmaz), U.S.
Pat. No. 4,800,882 (Gianturco), or U.S. Pat. No. 4,886,062
(Wiktor). Such designs include both metal and polymeric stents, as
well as self-expanding and balloon-expandable stents. Stents may
also used to deliver a drug at the site of contact with the
vasculature, as disclosed in U.S. Pat. No. 5,102,417 (Palmaz) and
in International Patent Application Nos. WO 91/12779 (Medtronic,
Inc.) and WO 90/13332 (Cedars-Sanai Medical Center), U.S. Pat. No.
5,419,760 (Narciso, Jr.) and U.S. Pat. No. 5,429,634 (Narciso,
Jr.), for example. Stents have also been used to deliver viruses to
the wall of a lumen for gene delivery, as disclosed in U.S. Pat.
No. 5,833,651 (Donovan et al.).
[0058] The term "deposited" means that the inhibitory agent is
coated, adsorbed, placed, or otherwise incorporated into the device
by methods known in the art. For example, the inhibitory agent may
be embedded and released from within ("matrix type") or surrounded
by and released through ("reservoir type") polymer materials that
coat or span the medical device. In the later example, the
inhibitory agent may be entrapped within the polymer materials or
coupled to the polymer materials using one or more the techniques
for generating such materials known in the art. In other
formulations, the inhibitory agent may be linked to the surface of
the medical device without the need for a coating by means of
detachable bonds and release with time, can be removed by active
mechanical or chemical processes, or are in a permanently
immobilized form that presents the inhibitory agent at the
implantation site.
[0059] In one embodiment, the inhibitory agent may be incorporated
with polymer compositions during the formation of biocompatible
coatings for medical devices, such as stents. The coatings produced
from these components are typically homogeneous and are useful for
coating a number of devices designed for implantation.
[0060] The polymer may be either a biostable or a bioabsorbable
polymer depending on the desired rate of release or the desired
degree of polymer stability, but a bioabsorbable polymer is
preferred for this embodiment since, unlike a biostable polymer, it
will not be present long after implantation to cause any adverse,
chronic local response. Bioabsorbable polymers that could be used
include, but are not limited to, poly(L-lactic acid),
polycaprolactone, polyglycolide (PGA), poly(lactide-co-glycolide)
(PLLA/PGA), poly(hydroxybutyrate),
poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester,
polyanhydride, poly(glycolic acid), poly(D-lactic acid),
poly(L-lactic acid), poly(D,L-lactic acid), poly(D,L-lactide)
(PLA), poly (L-lactide) (PLLA), poly(glycolic acid-co-trimethylene
carbonate) (PGA/PTMC), polyethylene oxide (PEO), polydioxanone
(PDS), polyphosphoester, polyphosphoester urethane, poly(amino
acids), cyanoacrylates, poly(trimethylene carbonate),
poly(iminocarbonate), copoly(ether-esters) (e.g., PEO/PLA),
polyalkylene oxalates, polyphosphazenes and biomolecules such as
fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic
acid, polyepsilon caprolactone, polyhydroxy butyric acid,
polyorthoesters, polyacetals, polydihydropyrans,
polycyanoacrylates, cross linked or amphipathic block copolymers of
hydrogels, and other suitable bioabsorbable poplymers known in the
art. Also, biostable polymers with a relatively low chronic tissue
response such as polyurethanes, silicones, and polyesters could be
used and other polymers could also be used if they can be dissolved
and cured or polymerized on the medical device such as polyolefins,
polyisobutylene and ethylene-alphaolefin copolymers; acrylic
polymers and copolymers, vinyl halide polymers and copolymers, such
as polyvinyl chloride; polyvinylpyrrolidone; polyvinyl ethers, such
as polyvinyl methyl ether; polyvinylidene halides, such as
polyvinylidene fluoride and polyvinylidene chloride;
polyacrylonitrile, polyvinyl ketones; polyvinyl aromatics, such as
polystyrene, polyvinyl esters, such as polyvinyl acetate;
copolymers of vinyl monomers with each other and olefins, such as
ethylene-methyl methacrylate copolymers, acrylonitrile-styrene
copolymers, ABS resins, and ethylene-vinyl acetate copolymers;
pyran copolymer; polyhydroxy-propyl-methacrylamide-phenol;
polyhydroxyethyl-aspartamide-phenol; polyethyleneoxide-polylysine
substituted with palmitoyl residues; polyamides, such as Nylon 66
and polycaprolactam; alkyd resins, polycarbonates;
polyoxymethylenes; polyimides; polyethers; epoxy resins,
polyurethanes; rayon; rayon-triacetate; cellulose, cellulose
acetate, cellulose butyrate; cellulose acetate butyrate;
cellophane; cellulose nitrate; cellulose propionate; cellulose
ethers; and carboxymethyl cellulose.
[0061] Polymers and semipermeable polymer matrices may be formed
into shaped articles, such as valves, stents, tubing, prostheses
and the like.
[0062] In one embodiment of the invention, the inhibitory agent of
the invention is coupled to a polymer or semipermeable polymer
matrix that is formed as a stent or stent-graft device.
[0063] Typically, polymers are applied to the surface of an
implantable device by spin coating, dipping or spraying. Additional
methods known in the art can also be utilized for this purpose.
Methods of spraying include traditional methods as well as
microdeposition techniques with an inkjet type of dispenser.
Additionally, a polymer can be deposited on an implantable device
using photo-patterning to place the polymer on only specific
portions of the device. This coating of the device provides a
uniform layer around the device which allows for improved diffusion
of various analytes through the device coating.
[0064] In preferred embodiments of the invention, the inhibitory
agent is formulated for release from the polymer coating into the
environment in which the medical device is placed. Preferably, the
inhibitory agent is released in a controlled manner over an
extended time frame (e.g., months) using at least one of several
well-known techniques involving polymer carriers or layers to
control elution. Some of these techniques were previously described
in U.S. Patent Application 20040243225A1.
[0065] Moreover, as described for example in U.S. Pat. No.
6,770,729, the reagents and reaction conditions of the polymer
compositions can be manipulated so that the release of the
inhibitory agent from the polymer coating can be controlled. For
example, the diffusion coefficient of the one or more polymer
coatings can be modulated to control the release of the inhibitory
agent from the polymer coating. In a variation on this theme, the
diffusion coefficient of the one or more polymer coatings can be
controlled to modulate the ability of an analyte that is present in
the environment in which the medical device is placed (e.g. an
analyte that facilitates the breakdown or hydrolysis of some
portion of the polymer) to access one or more components within the
polymer composition (and for example, thereby modulate the release
of the inhibitory agent from the polymer coating). Yet another
embodiment of the invention includes a device having a plurality of
polymer coatings, each having a plurality of diffusion
coefficients. In such embodiments of the invention, the release of
the inhibitory agent from the polymer coating can be modulated by
the plurality of polymer coatings.
[0066] In yet another embodiment of the invention, the release of
the inhibitory agent from the polymer coating is controlled by
modulating one or more of the properties of the polymer
composition, such as the presence of one or more endogenous or
exogenous compounds, or alternatively, the pH of the polymer
composition. For example, certain polymer compositions can be
designed to release a inhibitory agent in response to a decrease in
the pH of the polymer composition. Alternatively, certain polymer
compositions can be designed to release the inhibitory agent in
response to the presence of hydrogen peroxide.
V. Methods of Treating Diseases Modulated by CCR6
[0067] In one aspect, the present invention provides methods of
treating or preventing a CCR6-mediated condition or disease by
administering to a subject having such a condition or disease, a
therapeutically effective amount of any compound of the invention.
Preferred compounds for use in the present methods are those
compounds provided above as preferred embodiments, as well as
compounds specifically exemplified in the Examples below, and
provided with specific structures herein. The "subject" is defined
herein to include animals such as mammals, including, but not
limited to, primates (e.g., humans), cows, sheep, goats, horses,
dogs, cats, rabbits, rats, mice and the like. In preferred
embodiments, the subject is a human.
[0068] As used herein, the phrase "CCR6-mediated condition or
disease" and related phrases and terms refer to a condition or
disease characterized by inappropriate, e.g., less than or greater
than normal, CCR6 functional activity. Inappropriate CCR6
functional activity might arise as the result of CCR6 expression in
cells which normally do not express CCR6, increased CCR6 expression
(leading to, e.g., inflammatory and immunoregulatory disorders and
diseases) or decreased CCR6 expression. Inappropriate CCR6
functional activity might also arise as the result of CCL20
secretion by cells which normally do not secrete CCL20, increased
CCL20 expression (leading to, e.g., inflammatory and
immunoregulatory disorders and diseases) or decreased CCL20
expression. A CCR6-mediated condition or disease may be completely
or partially mediated by inappropriate CCR6 functional activity.
However, a CCR6-mediated condition or disease is one in which
modulation of CCR6 results in some effect on the underlying
condition or disease (e.g., a CCR6 antagonist results in some
improvement in patient well-being in at least some patients).
[0069] The term "therapeutically effective amount" means the amount
of the subject compound that will elicit the biological or medical
response of a tissue, system, animal or human that is being sought
by the researcher, veterinarian, medical doctor or other
clinician.
[0070] Diseases and conditions associated with inflammation,
infection and cancer can be treated or prevented with the present
compounds and compositions. In one group of embodiments, diseases
or conditions, including chronic diseases, of humans or other
species can be treated with inhibitors of CCR6 function. These
diseases or conditions include: (1) allergic diseases such as
systemic anaphylaxis or hypersensitivity responses, drug allergies,
insect sting allergies and food allergies, (2) inflammatory bowel
diseases, such as Crohn's disease, ulcerative colitis, ileitis and
enteritis, (3) vaginitis, (4) psoriasis and inflammatory dermatoses
such as dermatitis, eczema, atopic dermatitis, allergic contact
dermatitis, urticaria and pruritus, Vitiligo (5) vasculitis, (6)
spondyloarthropathies, (7) scleroderma, (8) asthma and respiratory
allergic diseases such as allergic asthma, allergic rhinitis,
hypersensitivity lung diseases and the like, (9) autoimmune
diseases, such as arthritis (including rheumatoid and psoriatic) as
well as for instance Hashimoto's thyroiditis and Grave's disease,
multiple sclerosis, systemic lupus erythematosus, type I diabetes,
glomerulonephritis, and the like, (10) graft rejection (including
allograft rejection and graft-v-host disease), and (11) other
diseases in which undesired inflammatory responses are to be
inhibited, such as atherosclerosis, myositis, neurodegenerative
diseases (e.g., Alzheimer's disease), encephalitis, meningitis,
hepatitis, nephritis, sepsis, sarcoidosis, allergic conjunctivitis,
otitis, chronic obstructive pulmonary disease, sinusitis, Behcet's
syndrome and gout.
[0071] Preferably, the present methods are directed to the
treatment of diseases or conditions selected from allergic
diseases, psoriasis, skin conditions such as atopic dermatitis and
asthma and scleroderma.
[0072] In another group of embodiments, modulation of CCR6
dependent regulatory T cell trafficking may be modulated to treat
diseases or conditions including cancers, infectious diseases
(viral infections, e.g., HIV infection, and bacterial infections)
and immunosuppressive diseases such as organ transplant conditions
and skin transplant conditions. The term "organ transplant
conditions" is meant to include bone marrow transplant conditions
and solid organ (e.g., kidney, liver, lung, heart, pancreas or
combination thereof) transplant conditions.
[0073] Depending on the disease to be treated and the subject's
condition, the compounds of the present invention may be
administered by oral, parenteral (e.g., intramuscular,
intraperitoneal, intravenous, ICV, intracisternal injection or
infusion, subcutaneous injection, or implant), inhalation, nasal,
vaginal, rectal, sublingual, or topical routes of administration
and may be formulated, alone or together, in suitable dosage unit
formulations containing conventional non-toxic pharmaceutically
acceptable carriers, adjuvants and vehicles appropriate for each
route of administration. The present invention also contemplates
administration of the compounds of the present invention in a depot
formulation.
[0074] Those of skill in the art will understand that agents that
modulate CCR6 activity can be combined in treatment regimens with
other therapeutic agents and/or with chemotherapeutic agents or
radiation. In some cases, the amount of chemotherapeutic agent or
radiation is an amount which would be sub-therapeutic if provided
without combination with a composition of the invention. Those of
skill in the art will appreciate that "combinations" can involve
combinations in treatments (i.e., two or more drugs can be
administered as a mixture, or at least concurrently or at least
introduced into a subject at different times but such that both are
in the bloodstream of a subject at the same time). Additionally,
compositions of the current invention may be administered prior to
or subsequent to a second therapeutic regimen, for instance prior
to or subsequent to a dose of chemotherapy or irradiation.
[0075] The compounds of the present invention are accordingly
useful in the prevention and treatment of a wide variety of
inflammatory and immunoregulatory disorders and diseases.
[0076] In the treatment or prevention of conditions which require
chemokine receptor modulation an appropriate dosage level will
generally be about 0.001 to 100 mg per kg patient body weight per
day which can be administered in single or multiple doses.
Preferably, the dosage level will be about 0.01 to about 25 mg/kg
per day; more preferably about 0.05 to about 10 mg/kg per day. A
suitable dosage level may be about 0.01 to 25 mg/kg per day, about
0.05 to 10 mg/kg per day, or about 0.1 to 5 mg/kg per day. Within
this range the dosage may be 0.005 to 0.05, 0.05 to 0.5 or 0.5 to
5.0 mg/kg per day. For oral administration, the compositions are
preferably provided in the form of tablets containing 1.0 to 1000
milligrams of the active ingredient, particularly 1.0, 5.0, 10.0,
15.0. 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0,
400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of
the active ingredient for the symptomatic adjustment of the dosage
to the patient to be treated. The compounds may be administered on
a regimen of 1 to 4 times per day, preferably once or twice per
day.
[0077] It will be understood, however, that the specific dose level
and frequency of dosage for any particular patient may be varied
and will depend upon a variety of factors including the activity of
the specific compound employed, the metabolic stability and length
of action of that compound, the age, body weight, hereditary
characteristics, general health, sex and diet of the subject, as
well as the mode and time of administration, rate of excretion,
drug combination, and the severity of the particular condition for
the subject undergoing therapy.
[0078] Diseases and conditions associated with inflammation, immune
disorder, infection and cancer can be treated or prevented with the
present compounds, compositions, and methods.
[0079] The compounds and compositions of the present invention can
be combined with other compounds and compositions having related
utilities to prevent and treat the condition or disease of
interest, such as inflammatory or autoimmune disorders, conditions
and diseases, including inflammatory bowel disease, rheumatoid
arthritis, osteoarthritis, psoriatic arthritis, polyarticular
arthritis, multiple sclerosis, allergic diseases, psoriasis, atopic
dermatitis and asthma, and those pathologies noted above.
[0080] For example, in the treatment or prevention of inflammation
or autoimmunity or for example arthritis associated bone loss, the
present compounds and compositions may be used in conjunction with
an anti-inflammatory or analgesic agent such as an opiate agonist,
a lipoxygenase inhibitor, such as an inhibitor of 5-lipoxygenase, a
cyclooxygenase inhibitor, such as a cyclooxygenase-2 inhibitor, an
interleukin inhibitor, such as an interleukin-1 inhibitor, an NMDA
antagonist, an inhibitor of nitric oxide or an inhibitor of the
synthesis of nitric oxide, a non steroidal anti-inflammatory agent,
or a cytokine-suppressing anti-inflammatory agent, for example with
a compound such as acetaminophen, aspirin, codeine, fentanyl,
ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin,
piroxicam, a steroidal analgesic, sufentanyl, sunlindac, tenidap,
and the like. Similarly, the instant compounds and compositions may
be administered with an analgesic listed above; a potentiator such
as caffeine, an H2 antagonist (e.g., ranitidine), simethicone,
aluminum or magnesium hydroxide; a decongestant such as
phenylephrine, phenylpropanolamine, pseudoephedrine, oxymetazoline,
ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo
desoxy ephedrine; an antitussive such as codeine, hydrocodone,
caramiphen, carbetapentane, or dextromethorphan; a diuretic; and a
sedating or non sedating antihistamine.
[0081] Likewise, compounds and compositions of the present
invention may be used in combination with other drugs that are used
in the treatment, prevention, suppression or amelioration of the
diseases or conditions for which compounds and compositions of the
present invention are useful. Such other drugs may be administered,
by a route and in an amount commonly used therefor,
contemporaneously or sequentially with a compound or composition of
the present invention. When a compound or composition of the
present invention is used contemporaneously with one or more other
drugs, a pharmaceutical composition containing such other drugs in
addition to the compound or composition of the present invention is
preferred. Accordingly, the pharmaceutical compositions of the
present invention include those that also contain one or more other
active ingredients or therapeutic agents, in addition to a compound
or composition of the present invention. Examples of other
therapeutic agents that may be combined with a compound or
composition of the present invention, either administered
separately or in the same pharmaceutical compositions, include, but
are not limited to: (a) VLA-4 antagonists, (b) corticosteroids,
such as beclomethasone, methylprednisolone, betamethasone,
prednisone, prenisolone, dexamethasone, fluticasone,
hydrocortisone, budesonide, triamcinolone, salmeterol, salmeterol,
salbutamol, formeterol; (c) immunosuppressants such as cyclosporine
(cyclosporine A, Sandimmune.RTM., Neoral.RTM.), tacrolirnus
(FK-506, Prograf.RTM.), rapamycin (sirolimus, Rapamune.RTM.),
Tofacitinib (Xeljanz.RTM.) and other FK-506 type
immunosuppressants, and mycophenolate, e.g., mycophenolate mofetil
(CellCept.RTM.); (d) antihistamines (H1-histamine antagonists) such
as bromopheniramine, chlorpheniramine, dexchloipheniramine,
triprolidine, clemastine, diphenhydramine, diphenylpyraline,
tripelennamine, hydroxyzine, methdilazine, promethazine, trim
eprazine, azatadine, cyproheptadine, antazoline, pheniramine
pyrilamine, astemizole, terfenadine, loratadine, cetirizine,
fexofenadine, descarboethoxyloratadine, and the like; (e) non
steroidal anti asthmatics (e.g., terbutaline, metaproterenol,
fenoterol, isoetharine, albuterol, bitolterol and pirbuterol),
theophylline, cromolyn sodium, atropine, ipratropium bromide,
leukotriene antagonists (e.g., zafmlukast, montelukast, pranlukast,
iralukast, pobilukast and SKB-106,203), leukotriene biosynthesis
inhibitors (zileuton, BAY-1005); (f) non steroidal
anti-inflammatory agents (NSAIDs) such as propionic acid
derivatives (e.g., alminoprofen, benoxaprofen, bucloxic acid,
carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen,
ibuprofen, indoprofen, ketoprofen, niroprofen, naproxen, oxaprozin,
pirprofen, pranoprofen, suprofen, tiaprofenic acid and
tioxaprofen), acetic acid derivatives (e.g., indomethacin,
acemetacin, alclofenac, clidanac, diclofenac, fenclofenac,
fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac,
sulindac, tiopinac, tolmetin, zidometacin and zomepirac), fenamic
acid derivatives (e.g., flufenamic acid, meclofenamic acid,
mefenamic acid, niflumic acid and tolfenamic acid),
biphenylcarboxylic acid derivatives (e.g., diflunisal and
flufenisal), oxicams (e.g., isoxicam, piroxicam, sudoxicam and
tenoxican), salicylates (e.g., acetyl salicylic acid and
sulfasalazine) and the pyrazolones (e.g., apazone, bezpiperylon,
feprazone, mofebutazone, oxyphenbutazone and phenylbutazone); (g)
cyclooxygenase-2 (COX-2) inhibitors such as celecoxib
(Celebrex.RTM.) and rofecoxib (Vioxx.RTM.); (h) inhibitors of
phosphodiesterase type IV (PDE IV); (i) gold compounds such as
auranofin and aurothioglucose, (j) etanercept (Enbrel.RTM.), (k)
antibody therapies such as orthoclone (OKT3), daclizumab
(Zenapax.RTM.), basiliximab (Simulect.RTM.) and infliximab
(Remicade.RTM.), adalimumab (Humira.RTM.), golimumab
(Simponi.RTM.), rituximab (Rituxan.RTM.), tocilizumab
(Actemra.RTM.), (1) other antagonists of the chemokine receptors,
especially CCR5, CXCR2, CXCR3, CCR2, CCR3, CCR4, CCR7, CX.sub.3CR1
and CXCR6; (m) lubricants or emollients such as petrolatum and
lanolin, (n) keratolytic agents (e.g., tazarotene), (o) vitamin D3
derivatives, e.g., calcipotriene or calcipotriol (Dovonex.RTM.),
(p) PUVA, (q) anthralin (Drithrocreme.RTM.), (r) etretinate
(Tegison.RTM.) and isotretinoin and (s) multiple sclerosis
therapeutic agents such as interferon .beta.-1.beta.
(Betaseron.RTM.), interferon (.beta.-1.alpha. (Avonex.RTM.),
azathioprine (Imurek.RTM., Imuran.RTM.), glatiramer acetate
(Capoxone.RTM.), a glucocorticoid (e.g., prednisolone) and
cyclophosphamide (t) DMARDS such as methotrexate and leflunomide
(u) other compounds such as 5-aminosalicylic acid and prodrugs
thereof; hydroxychloroquine; D-penicillamine; antimetabolites such
as azathioprine, 6-mercaptopurine and methotrexate; DNA synthesis
inhibitors such as hydroxyurea and microtubule disrupters such as
colchicine and proteasome inhibitors such as bortezomib
(Velcade.RTM.). The weight ratio of the compound of the present
invention to the second active ingredient may be varied and will
depend upon the effective dose of each ingredient. Generally, an
effective dose of each will be used. Thus, for example, when a
compound of the present invention is combined with an NSAID the
weight ratio of the compound of the present invention to the NSAID
will generally range from about 1000:1 to about 1:1000, preferably
about 200:1 to about 1:200. Combinations of a compound of the
present invention and other active ingredients will generally also
be within the aforementioned range, but in each case, an effective
dose of each active ingredient should be used.
VI. Examples
[0082] The following examples are offered to illustrate, but not to
limit the claimed invention.
[0083] Reagents and solvents used below can be obtained from
commercial sources such as Aldrich Chemical Co. (Milwaukee, Wis.,
USA). .sup.1H-NMR were recorded on a Varian Mercury 400 MHz NMR
spectrometer. Significant peaks are provided relative to TMS and
are tabulated in the order: multiplicity (s, singlet; d, doublet;
t, triplet; q, quartet; m, multiplet) and number of protons. Mass
spectrometry results are reported as the ratio of mass over charge,
followed by the relative abundance of each ion (in parenthesis). In
tables, a single m/e value is reported for the M+H (or, as noted,
M-H) ion containing the most common atomic isotopes. Isotope
patterns correspond to the expected formula in all cases.
Electrospray ionization (ESI) mass spectrometry analysis was
conducted on a Hewlett-Packard MSD electrospray mass spectrometer
using the HP1100 HPLC equipped with an Agilent Zorbax SB-C18,
2.1.times.50 mm, 5.mu. column for sample delivery. Normally the
analyte was dissolved in methanol at 0.1 mg/mL and 1 microlitre was
infused with the delivery solvent into the mass spectrometer, which
scanned from 100 to 1500 daltons. All compounds could be analyzed
in the positive ESI mode, using acetonitrile/water with 1% formic
acid as the delivery solvent. The compounds provided below could
also be analyzed in the negative ESI mode, using 2 mM NH.sub.4OAc
in acetonitrile/water as delivery system.
[0084] The following abbreviations are used in the Examples and
throughout the description of the invention: [0085] HPLC, High
Pressure Liquid Chromatography; DMF, Dimethyl formamide; TFA,
Trifluoroacetic Acid; THF, Tetrahydrofuran; EtOAc, Ethyl acetate;
BOC.sub.2O, di-tertbutyl dicarbonate or BOC anhydride; HPLC, High
Pressure Liquid Chromatography; DIPEA, Diisopropyl ethylamine;
HBTU, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate; dppf, 1,1'-Bis(diphenylphosphino)ferrocene;
Pd.sub.2(dba).sub.3, Tris(dibenzylideneacetone)dipalladium(0);
DIPEA, diisopropylethylamine; DMP, dimethylphthalate; Me, methyl;
Et, ethyl; DCM, dichloromethane.
[0086] Compounds within the scope of this invention can be
synthesized as described below, using a variety of reactions known
to the skilled artisan. One skilled in the art will also recognize
that alternative methods may be employed to synthesize the target
compounds of this invention, and that the approaches described
within the body of this document are not exhaustive, but do provide
broadly applicable and practical routes to compounds of
interest.
[0087] Certain molecules claimed in this patent can exist in
different enantiomeric and diastereomeric forms and all such
variants of these compounds are claimed.
[0088] The detailed description of the experimental procedures used
to synthesize key compounds in this text lead to molecules that are
described by the physical data identifying them as well as by the
structural depictions associated with them.
[0089] Those skilled in the art will also recognize that during
standard work up procedures in organic chemistry, acids and bases
are frequently used. Salts of the parent compounds are sometimes
produced, if they possess the necessary intrinsic acidity or
basicity, during the experimental procedures described within this
patent.
Example 1: Synthesis of Methyl
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline-8-carboxylate
##STR00010##
[0091] (a) To a stirred solution of H.sub.2O (80 mL) and
H.sub.2SO.sub.4 (120 mL) at 0.degree. C. was added
5-bromo-8-methylquinoline (25 g, 112.6 mmol). After obtaining a
solution, CrO.sub.3 was introduced (16 g, 157.6 mmol) in portion
wise while maintaining the internal temperature at 70.degree. C.
The reaction mixture was stirred for 1 h at 70.degree. C. An
additional CrO.sub.3 (16 g, 157.6 mmol) was added in portions and
stirred at 80.degree. C. for 2.5 h. After completion of the
reaction, it was cooled to r.t, poured onto crushed ice,
neutralized with aqueous ammonium hydroxide to get the solids. The
solids were filtered, dried under high vacuum for 16 h to get the
crude 5-bromoquinoline-8-carboxylic acid (28.0 g) as a green
colored solid.
[0092] (b) K.sub.2CO.sub.3 (61.3 g, 444.0 mmol) and methyl iodide
(63.1 g, 444.0 mmol) were added to a stirred suspension of
5-bromoquinoline-8-carboxylic acid (28.0 g, 111.0 mmol) in DMF (250
mL) at r.t. The reaction mixture was heated at 45.degree. C. for 36
h, cooled to r.t, filtered the solids, washed with ethyl acetate
(100 mL). The filtrate was diluted with water, extracted with ethyl
acetate (3.times.300 mL) and washed with water (3.times.100 mL).
The ethyl acetate layer was dried (Na.sub.2SO.sub.4), filtered and
concentrated under reduced pressure. The residue was purified by
flash column chromatography on silica gel, eluting with ethyl
acetate in hexanes (0-20%) to afford
methyl-5-bromoquinoline-8-carboxylate as a cream color solid (20.5
g, 70% for 2 steps). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.07
(dd, J=4.3, 1.5 Hz, 1H), 8.60 (dd, J=8.7, 1.6 Hz, 1H), 7.88 (s,
2H), 7.58 (dd, J=8.6, 4.0 Hz, 1H), 4.05 (s, 3H)
[0093] (c) A solution of methyl-5-bromoquinoline-8-carboxylate
(20.5 g, 77.06 mmol),
4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-
-dioxaborolane (21.4 g, 84.7 mmol), and KOAc (18.8 g, 192.6 mmol)
in dry 1,4-dioxane (200 mL) was purged with nitrogen gas for 10
min. Then, Pd(dppf)Cl.sub.2 (3.14 g, 7.70 mmol) was added and the
resulting mixture was heated at 95.degree. C. for 8 h, cooled to
r.t and the excess solvent was removed under vacuum. The residue
was diluted with ether, filtered through a Celite plug and washed
with ether (200 mL); the filtrate was concentrated under reduced
pressure. The resulting residue was purified by column
chromatography on silica gel, eluting with 0-50% ethyl acetate in
hexanes to afford a red color thick syrup/solid which was dissolved
in ether and cooled to -20.degree. C. and stored for 12 h, the
separated light pink color solid was filtered and dried to get pure
methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)
quinoline-8-carboxylate (17.5 g, 78%): .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 9.14 (dd, J=8.6, 0.6 Hz, 1H), 9.02-9.01 (m,
1H), 8.14 (d, J=7.0 Hz, 1H), 7.94 (d, J=7.0 Hz, 1H), 7.48 (dd,
J=8.6, 4.3 Hz, 1H), 4.06 (s, 3H), 1.43 (s, 12H).
Example 2: Synthesis of 3,4-dichloro-2-iodoaniline
##STR00011##
[0095] To a stirred suspension of 3,4-dichloroaniline (20 g, 123
mmol), HI (48%, 15.7 g, 123 mmol), H.sub.2O.sub.2 (30%, 8.3 g, 246
mmol) in H.sub.2O (62 mL) at r.t. The reaction mixture was stirred
in dark at r.t for overnight. The supernatant was discarded,
diluted with ethyl acetate:hexanes (1:10), quenched with saturates
NaHSO.sub.3, stirred for 1 h at ambient temperature, filtered the
solids. The filtrate was washed with water, saturated aqueous
NaHCO.sub.3, dried (Na2SO4), filtered and concentrated to get 1:4
regioisomeric mixture of iodo derivative (minor isomer is
required). It was recrystallized from cyclohexane to afford 1:1
mixture of regioisomers enriched in the filtrate. This mixture was
further purified by flash column chromatography on silica gel,
eluting with ethyl acetate:hexanes (0-2%) to get the required
compound as a cream color solid (5.2 g, .about.15% yield). .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 7.22 (d, J=8.6 Hz, 1H), 6.60 (d,
J=8.6 Hz, 1H), 4.32 (br, 2H).
Example 3: 3-chloro-2-iodo-4-(trifluoromethoxy)aniline
##STR00012##
[0097] The title compound was synthesized in a similar fashion to
Example 2 in 18% yield. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.11 (d, J=8.9 Hz, 1H), 6.67 (d, J=8.9 Hz, 1H), 4.30 (br, 2H).
Example 4: Synthesis of
2-bromo-3-fluoro-4-trifluoromethoxyaniline
##STR00013##
[0099] (a) In a 20 mL vial was added
3-fluoro-4-trifluoromethoxyaniline (150 mg, 0.769 mmol) in acetic
acid (0.5 mL) at room temperature. Bromine (118 .mu.L, 2.30 mmol, 3
eq.) was added and the reaction was stirred for several hours.
Dichloromethane (2 mL) was added to break up the solidified
reaction mixture, followed by more bromine (40 .mu.L, 0.781 mmol, 1
eq.) addition. After stirring for another hour, dichloromethane was
removed by gently blowing a stream of nitrogen to the reaction
mixture. The solid was filtered and washed thoroughly with water
and then dried under vacuum to give 2,
6-dibromo-3-fluoro-4-trifluoromethoxyaniline as a white solid (172
mg, 0.489 mmol, 64% yield).
[0100] (b) In a 40 mL vial was added 2,
6-dibromo-3-fluoro-4-trifluoromethoxyaniline (172 mg, 0.489 mmol),
followed by tin(II) chloride dihydrate (122 mg, 0.540 mmol, 1.1
eq.). Acetic acid (725 .mu.L) and concentrated hydrochloric acid
(580 .mu.L) was added to make a solution. The reaction mixture was
heated at 115.degree. C. for 1.5 hours. After cooling the reaction
to room temperature, most of acetic acid was removed under vacuum.
Water was added and the product was extracted with dichloromethane
three times. The organic layer was dried over anhydrous sodium
sulfate. After removing the solvent under reduced pressure, the
crude material was purified using silica gel column chromatography.
The recovered 2, 6-dibromo-3-fluoro-4-trifluoromethoxyaniline was
eluted using a gradient of 5-10% ethyl acetate in hexanes followed
by the desired product, 2-bromo-3-fluoro-4-trifluoromethoxyaniline,
which was eluted with 15% ethyl acetate in hexanes (64.8 mg, 0.236
mmol, 48%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.06 (dd,
J=9.0, 9.0 Hz, 1H), 6.52 (dd, J=9.0, 2.0 Hz, 1H), 4.27 (br,
2H).
Example 5: Synthesis of
4-chloro-5-bromo-6-amino-2,2-diflouro-1,3-benzodioxole
##STR00014##
[0102] (a) To a stirred solution of
4-amino-2,2-diflouro-1,3-benzodioxole (2.5 g, 14.4 mmol) in
dichloromethane at 0.degree. C. was added N-bromosuccinimide (2.7
g, 15.2 mmol) portion wise. The solution was stirred at 0.degree.
C. for 30 min, then at room temperature for 1 h. The reaction
mixture was quenched with 1M sodium thiosulfate solution and
diluted with deionized water, extracted with dichloromethane
(2.times.50 mL). The combined organic layers were dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
product was purified by flash chromatography (SiO.sub.2, 0-20%
ethyl acetate in hexanes) to recover starting material 1 g and
afford 5-bromo-4-amino-2,2-diflouro-1,3-benzodioxole as colorless
oil (2.33 g, 9.25 mmol, 64%). MS: (ES) m/z calculated for
C.sub.7H.sub.4BrF.sub.2NO [M+H].sup.+ 252.0, found 252.
[0103] (b) To a stirred solution of copper (II) chloride (2.49 g,
18.5 mmol) and tert-butyl nitrite (2.39 g, 23.13 mmol) in
acetonitrile at 55.degree. C. was added a solution of
5-bromo-4-amino-2,2-diflouro-1,3-benzodioxole (2.33 g, 9.25 mmol)
in acetonitrile. The solution was stirred at 55.degree. C. for 30
min, then cool down to room temperature. The reaction mixture was
quenched with 5% hydrochloric acid solution and diluted with
deionized water, extracted with ethyl acetate (2.times.50 mL). The
organic layers were dried (Na.sub.2SO.sub.4), filtered, and
concentrated in vacuo. The crude product was purified by flash
chromatography (SiO.sub.2, 0-20% ethyl acetate in hexanes) to
afford 5-bromo-4-chloro-2,2-diflouro-1,3-benzodioxole as yellowish
oil (1.5 g, 5.53 mmol, 60%). MS: (ES) m/z calculated for
C.sub.7H.sub.2BrClF.sub.2O.sub.2 [M+H].sup.+ 272.0, no MS
found.
[0104] (c) The solution of
5-bromo-4-chloro-2,2-diflouro-1,3-benzodioxole (1.5 g, 5.53 mmol)
in 10 mL conc. sulfuric acid was cooled to -10.degree. C. Then a
solution of 1 mL fuming nitric acid and 2 mL of conc. sulfuric acid
was added drop wise. The resulting solution was stirred at
-10.degree. C. for .about.2 h. Then the reaction mixture was poured
into ice water and a yellow solid precipitated out. Filtered off
the solid, rinsed with water and collected the solid. The crude
solid was purified by flash chromatography (SiO.sub.2, 0-5% ethyl
acetate in hexanes) to afford pure
6-nitro-5-bromo-4-chloro-2,2-diflouro-1,3-benzodioxole (1.0 g, 3.16
mmol, 57%). MS: (ES) m/z calculated for C.sub.7HBrClF.sub.2NO.sub.4
[M+H].sup.+ 316.0, found 316.
[0105] (d) To the slurry of
6-nitro-5-bromo-4-chloro-2,2-diflouro-1,3-benzodioxole (1.0 g, 3.16
mmol) in ethanol (4 mL) and water (1 mL) was added ammonium
chloride (3.38 g, 63.2 mmol) and iron powder (1.06 g, 18.96 mmol).
The mixture was warmed up to 90.degree. C. for 1 h and then cooled
down. Filtered through a Celite plug and concentrated in vacuo. The
crude product was purified by flash chromatography (SiO.sub.2,
0-30% ethyl acetate in hexanes) to afford
6-amino-5-bromo-4-chloro-2,2-diflouro-1,3-benzodioxole as a white
solid (0.90 g, 3.16 mmol, 100%). MS: (ES) m/z calculated for
C.sub.7H.sub.3BrClF.sub.2NO.sub.2 [M+H].sup.+ 286.0, found 286.
Example 6: Synthesis of
2,2-difluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo-[d]
[1,3]dioxol-5-amine
##STR00015##
[0107] The title compound was synthesized in a similar fashion to
Example 1 in 55% yield. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.22 (s, 1H), 6.31 (s, 1H), 4.80 (br, 2H), 1.34 (s, 12H).
Example 7: Synthesis of
2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethoxy)anili-
ne
##STR00016##
[0109] The title compound was synthesized in a similar fashion to
Example 1. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.43 (br, 1H),
7.10 (dd, J=4.2, 1.8 Hz, 1H), 6.55 (d, J=7.1 Hz, 1H), 1.34 (s,
12H).
Example 8: Synthesis of
5-[6-[(4-tert-butyl-3-fluorophenyl)sulfonylamino]-2,2-difluoro-1,3-benzod-
ioxol-5-yl]quinoline-8-carboxylic Acid
##STR00017##
[0111] (a) To a solution of
2,2-difluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzodio-
xol-5-amine (Example 5, 2.7 g, 9.03 mmol) in dry pyridine (12 mL)
was added the 4-tert-butyl-3-fluorophenylsulfonyl chloride (2.82 g,
11.28 mmol) and the reaction mixture was heated at 80.degree. C.
for overnight. It was cooled to r.t. excess solvent was removed in
vacuo. The residue was diluted with saturated aqueous ammonium
chloride, extracted with DCM, purified by flash column using
hexanes: ethyl acetate mixture as an eluent on silica column to get
the pure compound (3.28 g, 71%)
[0112] (b) A mixture of the
4-tert-butyl-N-[2,2-difluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2--
yl)-1,3-benzodioxol-5-yl]-3-fluorobenzenesulfonamide (3.2 g, 6.22
mmol), methyl-5-bromoquinoline-8-carboxylate (Example 1, step-b,
1.66 g, 6.22 mmol) and 2 M aq. K.sub.2CO.sub.3 (7.8 mL, 15.55 mmol)
in 1,4-dioxane (50 mL) was purged with nitrogen for 5 minutes.
Pd(PPh.sub.3).sub.4 (360 mg, 0.31 mmol, 5 mol %) was added and the
reaction mixture was heated at 95.degree. C. for overnight. The
reaction mixture was cooled to r.t. LiOH.H.sub.2O (2.6 g, 62.2
mmol) was added and heated at 80.degree. C. for 1 hour. Cooled to
r.t, pH of the reaction medium was adjusted to .about.6 with 2N
aq.HCl, extracted with ethyl acetate, dried (Na.sub.2SO.sub.4),
filtered and concentrated. The residue was triturated with methanol
to get pure (>95%) title compound as an off-white solid (1.75 g,
50%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.96-8.94 (m, 1H),
8.57 (d, J=7.4 Hz, 1H), 7.93-7.91 (m, 1H), 7.57-7.54 (m, 2H), 7.42-
(t, J=7.8 Hz, 1H), 7.30-7.26 (m, 1H), 7.18-7.15 (m, 1H), 7.05 (d,
J=7.5 Hz, 1H), 6.88 (s, 1H), 6.56 (br, 1H), 1.43 (s, 9H); MS: (ES)
m/z calculated for C.sub.27H.sub.21F.sub.3N.sub.2O.sub.6S
Example 9: Synthesis of
5-[2-[(4-tert-butyl-3-fluorophenyl)sulfonylamino]-5-(trifluoromethoxy)phe-
nyl]quinoline-8-carboxylic Acid
##STR00018##
[0114] The title compound was synthesized in a similar fashion to
Example 8. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 9.02 (dd,
J=4.4, 1.6 Hz, 1H), 8.60 (d, J=7.5 Hz, 1H), 8.07 (dd, J=8.6, 1.7
Hz, 1H), 7.67 (dd, J=8.7, 4.4 Hz, 1H), 7.56 (d, J=8.9 Hz, 1H), 7.47
(ddt, J=9.0, 1.9, 1.1 Hz, 1H), 7.39-7.24 (m, 3H), 7.14 (dd, J=8.3,
2.0 Hz, 1H), 7.03 (dd, J=12.0, 2.0 Hz, 1H), 1.39 (s, 9H); MS: (ES)
m/z calculated for C.sub.27H.sub.22F.sub.4N.sub.2O.sub.5S
[M+H].sup.+ 558.12 found 558.1.
Example 10:
5-[2-[(4-tert-butyl-3-fluorophenyl)sulfonylamino]-5-chlorophenyl]quinolin-
e-8-carboxylic Acid
##STR00019##
[0116] The title compound was synthesized in a similar fashion to
Example 8. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 9.10 (dd,
J=4.7, 1.6 Hz, 1H), 8.66 (d, J=7.8 Hz, 1H), 8.27 (dd, J=8.6, 1.6
Hz, 1H), 7.78 (dd, J=8.6, 4.7 Hz, 1H), 7.54 (dd, J=8.6, 2.7 Hz,
1H), 7.41-7.36 (m, 3H), 7.16 (dd, J=8.2, 1.9 Hz, 1H), 7.06 (dd,
J=11.1, 1.9 Hz, 1H), 1.40 (s, 9H); MS: (ES) m/z calculated for
C.sub.26H.sub.22ClFN.sub.2O.sub.4S [M+H].sup.+ 513.1 found
513.1.
Example 11: Synthesis of
5-[6-[(4-tert-butyl-3-fluorophenyl)sulfonylamino]-2,3-dichlorophenyl]quin-
oline-8-carboxylic Acid
##STR00020##
[0118] (a) To a solution of 3,4-dichloro-2-iodoaniline (example 2,
2.2 g, 7.67 mmol) in dry pyridine (8 mL) was added
4-tert-butyl-3-fluorophenylsulfonyl chloride (2.11 g, 8.43 mmol)
and the reaction mixture was heated at 80.degree. C. for overnight.
LCMS indicated presence of mono and bis-sulfonamides. 10 N aq. NaOH
(3 mL) and ethanol (2 mL) were added to hydrolyze the
bis-sulfonamide. The reaction mixture was then heated at 80.degree.
C. for 2 h. It was cooled to r.t, excess solvent was removed in
vacuo to afford a dark brown solid, diluted with DCM, washed with
1N aq.HCl, and purified by flash column using hexanes: ethyl
acetate mixture as an eluent on silica column to get the pure
4-tert-butyl-N-(3,4-dichloro-2-iodophenyl)-3-fluorobenzsulfonamide
as an off white solid (3.5 g, 91%)
[0119] (b) A mixture of
4-tert-butyl-N-(3,4-dichloro-2-iodophenyl)-3-fluorobenzsulfonamide
(9 g, 17.9 mmol), Methyl
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline-8-carboxylate
(7.8 g, 25.1 mmol), K.sub.3PO.sub.4.H.sub.2O (10.3 g, 44.75 mmol)
and SPhos (0.73 g, 1.79 mmol) in n-BuOH:H.sub.2O (75:25 mL) solvent
system was purged with nitrogen for 15 minutes. Then
Pd.sub.2(dba).sub.3 (0.65 g, 0.72 mmol) was added and heated at
85.degree. C. for 6 h, cooled to r.t, filtered through a Celite
plug, washed with ethyl acetate and the filtrate was concentrated
in vacuo. The crude product was diluted with THF/H.sub.2O (60/10
mL) and lithium hydroxide monohydrate (7.52 g, 179 mmol) was added.
The reaction mixture was then heated at 60.degree. C. for
overnight, cooled to r.t, the pH was adjusted to .about.6 by 2N aq.
HCl, extracted with ethyl acetate (3.times.500 mL), the combined
ethyl acetate layer was washed with water, brine, dried
(Na.sub.2SO.sub.4), filtered and concentrated. The residue was
purified by flash column using ethyl acetate and hexanes as eluents
to get the product which was further triturated from methanol to
afford the title compound as an off-white solid (7.2 g, 73%).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.98 (dd, J=4.4, 1.6 Hz,
1H), 8.69 (d, J=7.5 Hz, 1H), 7.77-7.69 (m, 2H), 7.63 (d, J=9.0 Hz,
1H), 7.52 (dd, J=8.6, 4.3 Hz, 1H), 7.42 (t, J=8.0 Hz, 1H), 7.32
(dd, J=4.4, 1.6 Hz, 1H), 7.17 (dd, J=11.4, 2.0 Hz, 1H), 7.05 (d,
J=7.5 Hz, 1H), 6.30 (s, 1H), 1.48 (s, 9H); MS: (ES) m/z calculated
for C.sub.26H.sub.21FN.sub.2O.sub.4S [M+H].sup.+ 547.06 found
547.1.
Example 12:
5-[2-[(4-tert-butyl-3-fluorophenyl)sulfonylamino]-5-cyanophenyl]quinoline-
-8-carboxylic Acid Bis Sodium Salt
##STR00021##
[0121] The title compound was synthesized in a similar fashion to
Example 11.
[0122] 0.1 N aq. NaOH (2 eq) was added to the free acid suspended
in acetonitrile and water and lyophilized to get the bis sodium
salt. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 9.10 (dd, J=4.8,
1.6 Hz, 1H), 8.69 (d, J=7.5 Hz, 1H), 8.19 (dd, J=8.7, 1.7 Hz, 1H),
7.89 (dd, J=8.5, 2.1 Hz, 1H), 7.81-7.68 (m, 3H), 7.51-7.38 (m, 2H),
7.32 (dd, J=8.3, 2.0 Hz, 1H), 7.22 (dd, J=11.9, 2.0 Hz, 1H), 1.41
(s, 9H); MS: (ES) m/z calculated for
C.sub.27H.sub.22FN.sub.3O.sub.4S [M+H].sup.+ 504.13 found 504.
Example 13: Synthesis of
5-[6-[(4-tert-butyl-3-fluorophenyl)sulfonylamino]-2-fluoro-3-(trifluorome-
thoxy)phenyl]quinoline-8-carboxylic Acid
##STR00022##
[0124] The title compound was synthesized in a similar fashion to
Example 11. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.00 (dd,
J=4.3, 1.7 Hz, 1H), 8.72 (d, J=7.5 Hz, 1H), 7.86 (dt, J=8.6, 1.5
Hz, 1H), 7.64-7.54 (m, 2H), 7.53-7.33 (m, 3H), 7.30-7.18 (m, 2H),
1.42 (s, 9H); MS: (ES) m/z calculated for
C.sub.27H.sub.21N.sub.2O.sub.5SF.sub.5 [M-H].sup.- 579.1, found
579.1.
Example 14: Synthesis of
5-[6-[(4-tert-butylphenyl)sulfonylamino]-2-chloro-3-(trifluoromethoxy)phe-
nyl]quinoline-8-carboxylic Acid Bis Sodium Salt
##STR00023##
[0126] The title compound was synthesized in a similar fashion to
Example 11. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.79-8.77 (m,
1H), 7.72 (d, J=7.4 Hz, 1H), 7.57-7.54 (m, 1H), 7.52 ((d, J=9.4 Hz,
1H), 7.38-7.35 (m, 2H), 7.32-7.29 (m, 2H), 7.23-7.18 (m, 2H), 6.99
(d, J=7.4 Hz, 1H), 1.32 (s, 9H); MS: (ES) m/z calculated for
C.sub.27H.sub.22ClF.sub.3N.sub.2O.sub.5S [M+H].sup.- 579.09, found
579.1.
Example 15: Synthesis of
5-[6-[(4-tert-butylphenyl)sulfonylamino]-2-chloro-3-(trifluoromethoxy)phe-
nyl]quinoline-8-carboxylic Acid
##STR00024##
[0128] The title compound was synthesized in a similar fashion to
Example 11. .sup.1H NMR (400 MHz, CD.sub.3OD 9.06 (dd, J=4.8, 1.6
Hz, 1H), 8.61 (d, J=8.0 Hz, 1H), 7.94 (dd, J=8.8, 1.6 Hz, 1H),
7.72-7.60 (m, 3H), 7.42 (t, J=8.1 Hz, 1H), 7.20 (dd, J=8.0, 1.6 Hz,
1H), 7.16-7.06 (m, 2H), 1.42 (s, 9H); MS: (ES) m/z calculated for
C.sub.27H.sub.21ClF.sub.4N.sub.2O.sub.5S [M+H].sup.+ 597.08 found
597.1.
Example 16: Synthesis of
5-[6-[(4-tert-butyl-3-fluorophenyl)sulfonylamino]-4-chloro-2,2-difluoro-1-
,3-benzodioxol-5-yl]quinoline-8-carboxylic Acid
##STR00025##
[0130] The title compound was synthesized in a similar fashion to
Example 11. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 9.08 (dd,
J=4.7, 1.6 Hz, 1H), 8.58 (d, J=7.4 Hz, 1H), 8.11 (dd, J=8.6, 1.6
Hz, 1H), 7.72 (dd, J=8.6, 4.7 Hz, 1H), 7.43-7.39 (m, 2H), 7.18 (dd,
J=8.2, 2.0 Hz, 1H), 7.08 (dd, J=10.2, 2.0 Hz, 1H), 1.40 (s, 9H);
MS: (ES) m/z calculated for
C.sub.27H.sub.20ClF.sub.3N.sub.2O.sub.6S [M+H].sup.- 593.07, found
593.1.
Example 17: Synthesis of
4-tert-butyl-N-[2,2-difluoro-6-[8-(1H-tetrazol-5-yl)-5-quinolyl]-1,3-benz-
odioxol-5-yl]-3-fluorobenzenesulfonamide
##STR00026##
[0132] (a) A mixture of 5-bromo-8-iodoquinoline (0.52 g, 1.55
mmol), Zn(CN).sub.2 (218 mg, 1.86 mmol), and dppf (103 mg, 0.186
mmol) in DMF (2.5 mL) was purged with N.sub.2 (gas) for 5 minutes.
Pd.sub.2(dba).sub.3 (85 mg, 0.093 mmol) was added and the resulting
mixture was heated at 95.degree. C. for 5 h. After completion of
the reaction, it was cooled to r.t., diluted with water, and the
aqueous solution was extracted with ethyl acetate (3.times.50 mL).
The combined organic layer was washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated under reduced pressure. The crude
product was purified by column chromatography on silica gel,
eluting with ethyl acetate-hexanes (5-25%) to get
5-bromoquinoline-8-carbonitrile as a brown solid (72 mg).
[0133] (b) The Suziki reaction was carried out similar to Example
8. 72 mg of the starting material afforded 70 mg of the
product.
[0134] (c) To a stirred solution of the above nitrile (35 mg, 0.064
mmol) in H.sub.2O/IPA (5:1, 2 mL) at r.t were added ZnBr.sub.2 (43
mg, 0.324 mmol) and NaN.sub.3 (21 mg, 0.324 mmol). The reaction
mixture was heated at 100.degree. C. for 16 h. After completion of
the reaction, it was cooled to r.t and neutralized with 1N aq. HCl.
The aqueous solution was extracted with ethyl acetate (2.times.25
mL) and the combined organic layers were washed with brine, dried
over Na.sub.2SO.sub.4, filtered and concentrated under reduced
pressure. The crude product was triturated with methanol to give
the title compound as a brownish solid (8 mg). .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 9.84 (s, 1H), 9.04 (dd, J=4.2, 1.7 Hz,
1H), 8.45 (d, J=7.5, Hz, 1H), 7.87 (dd, J=8.6, 1.7 Hz, 1H), 7.58
(dd, J=8.6, 4.2 Hz, 1H), 7.43 (d, J=12.6 Hz, 1H), 7.24 (t, J=8.1,
Hz, 1H), 7.16-7.0 (m, 3H), 1.24 (s, 9H); MS: (ES) m/z calculated
for C.sub.28H.sub.22F.sub.3N.sub.5O.sub.4S [M+H].sup.+ 582.13 found
582.1.
Example 18: Synthesis of
5-[2-[(4-tert-butylphenyl)sulfonylamino]-5-cyanophenyl]quinoline-8-carbox-
ylic Acid
##STR00027##
[0136] The title compound was synthesized in a similar fashion to
Example 11. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.00 (dd,
J=4.3, 1.6 Hz, 1H), 8.68 (d, J=7.4 Hz, 1H), 7.92 (d, J=8.6 Hz, 1H),
7.87 (dd, J=8.6, 1.2 Hz, 1H), 7.78 (dd, J=9.0, 2.0 Hz, 1H),
7.62-7.50 (m, 5H), 7.45 (d, J=7.9 Hz, 1H), 7.19 (d, J=7.5 Hz, 2H),
6.67 (s, 1H), 1.37 (s, 9H); MS: (ES) m/z calculated for
C.sub.27H.sub.23N.sub.3O.sub.4S [M+H].sup.+ 486.14 found 486.1.
Example 19: Synthesis of
5-[6-[(4-tert-butylphenyl)sulfonylamino]-2-chloro-3-cyanophenyl]quinoline-
-8-carboxylic Acid Trifluoroacetic Acid Salt
##STR00028##
[0138] The title compound was synthesized in a similar fashion to
Example 11. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.85 (bs, 1H),
9.12-9.13 (m, 1H), 8.48 (d, J=7.4 Hz, 1H), .delta. 8.06 (bs, 1H),
7.89-7.87 (m, 1H), 7.70-7.52 (m, 7H), 7.16 (d, J=6.7 Hz, 1H), 1.30
(s, 9H); MS: (ES) m/z calculated for
C.sub.27H.sub.22ClN.sub.3O.sub.4S [M+H].sup.- 520.09, found
520.1.
Example 20: Synthesis of
5-[6-[(4-tert-butylphenyl)sulfonylamino]-3-cyano-2-fluorophenyl]quinoline-
-8-carboxylic Acid Hydrochloric Acid Salt
##STR00029##
[0140] The title compound was synthesized in a similar fashion to
Example 11. .sup.1H NMR (400 MHz, CDCl.sub.3 9.04 (dd, J=4.3, 1.6
Hz, 1H), 8.76 (d, J=7.4 Hz, 1H), 7.84-7.75 (m, 3H), 7.64-7.53 (m,
5H), 7.22 (d, J=7.4 Hz, 1H), 6.59 (bs, 1H) 1.37 (s, 9H); MS: (ES)
m/z calculated for C.sub.27H.sub.22FN.sub.3O.sub.4S [M+H].sup.+
504.1 found 504.4.
Biological Example 1: Ligand Binding Assay
[0141] Ligand binding assay was used to determine the ability of
potential CCR6 antagonists to block the interaction between CCR6
and its ligand CCL20 (MIP3alpha). L1.2 cells stably expressing the
CCR6 receptor, were centrifuged and resuspended in assay buffer (20
mM HEPES pH 7.1, 140 mM NaCl, 1 mM CaCl.sub.2), 5 mM MgCl.sub.2,
0.1% sodium azide and with 0.1% bovine serum albumin) to a
concentration of 5.times.10 5 cells/mL. Binding assays were set up
as follows. First, 0.1 mL of cells (5.times.104 cells/well) was
added to the assay plates containing the compounds, giving a final
concentration of .about.2-10 uM each compound for screening (or
part of a dose response for compound IC50 determinations). Then 0.1
mL of .sup.125I labeled CCL20 (obtained from PerkinElmer; Waltham,
Mass.) diluted in assay buffer to a final concentration of
.about.50 pM, yielding .about.30,000 cpm per well, was added, the
plates sealed and incubated for approximately 3 hours at 25.degree.
C. on a shaker platform. Reactions were aspirated onto GF/B glass
filters pre-soaked in 0.3% polyethyleneimine (PEI) solution, on a
vacuum cell harvester (Packard Instruments; Meriden, Conn.).
Scintillation fluid (50 uL; Microscint 20, Packard Instruments) was
added to each well, the plates were sealed and radioactivity
measured in a Top Count scintillation counter (Packard
Instruments). Control wells containing either diluent only (for
total counts) or 20 uM compound were used to calculate the percent
of total inhibition for compound. The computer program Prism from
GraphPad, Inc. (San Diego, Ca) was used to calculate IC50 values.
IC50 values are those concentrations required to reduce the binding
of labeled TARC to the receptor by 50%. Compounds in FIG. 1 having
an IC50 value in the binding assay of less than 100 nM are labeled
(+++); from 100-500 nM are labeled (++); and less than or equal to
20 .mu.M but above 500 nM are labeled (+).
Biological Example 2: Migration/Chemotaxis Assay
[0142] A serum chemotaxis assay was used to determine the efficacy
of potential receptor antagonists at blocking the migration
mediated through chemokine receptors, such as CCR6. This assay was
routinely performed using the ChemoTX.RTM. microchamber system with
a 5-.mu.m pore-sized polycarbonate membrane. To begin such an
assay, chemokine-receptor expressing cells (such as L1.2 cells
stably expressing CCR6) were collected by centrifugation at
400.times.g at room temperature, then suspended at 50 million/ml in
human serum. The compound being tested or an equivalent volume of
its solvent (DMSO) was then added to the cell/serum mixture at a
final DMSO concentration of 0. 25% (v/v). Separately, recombinant
human CCL20 was diluted with chemotaxis buffer (HESS+0.1% BSA),
generally spanning a range from 0.01 nM to 500 nM, after which 29
.mu.l of diluted chemokine was placed in the lower wells of the
ChemoTX.RTM. plate. The 5-.mu.m (pore size) polycarbonate membrane
was placed onto the plate, and 20 .mu.L of the cell/compound
mixture was transferred onto each well of the membrane. The plates
were incubated at 37.degree. C. for 90 minutes, after which the
polycarbonate membranes were removed and 5 .mu.l of the
DNA-intercalating agent CyQUANT (Invitrogen, Carlsbad, Calif.) was
added to the lower wells. The amount of fluorescence, corresponding
to the number of migrated cells, was measured using a Spectrafluor
Plus plate reader (TECAN, San Jose, Calif.).
[0143] (a) Evaluation of a Compound of Interest in an Oxazalone
Induced Model of DTH
[0144] Compounds of the invention were assessed in the murine model
of dermal delayed type hypersensitivity (DTH) induced by oxazolone.
Briefly, 8-10 week old BALB/c mice were sensitized topically with a
1% solution of oxazolone dissolved in ethanol on their shaved
abdomens on day 0. On day 6 post sensitization mice were dosed
orally with either vehicle or increasing doses of compounds 1.061
and 1.033 of the invention immediately prior to and 4 hours
following a topical challenge with a 0.5% solution of oxazolone in
ethanol on the right ear. The following day (day 7), ear
thicknesses were measured using caliper measurements. Animals
treated with compound had significantly reduced ear swelling
compared to vehicle treated controls indicating a compound mediated
decrease in oxazolone induced dermal hypersensitivity.
[0145] (b) Evaluation of a Compound of Interest in an Imiquimod
Induced Model of Psoriasis
[0146] Multiple mouse models of psoriasis are known. For example,
in the Imiquimod-induced mouse model of psoriasis, hair was removed
from the back of balb/c mice three days prior to the application of
5% Imiquimod once a day. Vehicle (1% HPMC) or CCR6 compound was
administered eg. orally at between 5 and 200 mg/kg once/twice daily
at the initiation of Imiquimod application and continued for five
to ten days. Therapeutic value was assessed using the following
methodologies: daily electronic caliper measurements and
immunohistochemistry at the end point to assess skin thickening,
flow cytometry and immunofluorescence at the end point to measure
leukocyte infiltration and inflammation, and mRNA quantitation via
Luminex at days two and five to assess molecular changes. Treatment
of animals with compound 1.033 or 1.061 of the invention resulted
in a significant improvement in disease.
[0147] (c) Evaluation of a Compound of Interest in an IL-23 Induced
Model of Psoriasis.
[0148] Another method to induce phenotypic changes associated with
psoriasis involved intra-dermal injections of IL-23. Briefly, 500
ng of recombinant murine IL-23 was intra-dermally injected every
other day into the right ear of C57BL6/N mice for a total of 5-6
administrations over a period of ten to twelve days. Concomitantly,
PBS was intra-dermally injected every other day into the left ear
of the same mice. CCR6 compound was dosed prophylactically at eg.
between 5-200 mg/kg once/twice daily via the oral or other route.
Therapeutic dosing was performed by orally providing IL-23
challenged mice with vehicle control for four days. On the fifth
day, animals were dosed with a compound of the invention at eg.
5-200 mg/kg once/twice daily via the oral or other route (at this
point, two rounds of IL-23 have been intra-dermally injected into
the right ear). Efficacy was assessed quantitatively by manually
measuring ear thickness using a caliper daily. Treatment of animals
with compound 1.033 or 1.061 of the invention resulted in a
significant improvement in disease.
[0149] (d) Evaluation of a Compound of Interest in a Mouse Model of
Septic Shock.
[0150] This example describes a procedure to evaluate the efficacy
of CCR6 antagonists for treatment of septic shock. An animal model
of endotoxic shock can be induced by injecting rodents with
lipopolysaccharide (LPS). Three series of mouse groups, comprising
15 mice per group, are treated with an intra-peritoneal injection
of an L.D. (lethal dose)-90 of LPS. One series of mice additionally
receives phosphate buffered saline (PBS) and Tween 0.5% i.p. 30
minutes before LPS administration. A second series consists of
groups of mice receiving different doses of the CCR6 antagonist
given either intra-peritoneally, intra-venously, sub-cutaneously,
intra-muscularly, orally, or via any other mode of administration
30 minutes before, or concurrently with, LPS administration. A
third series of mice, serving as positive control, consists of
groups treated with either mouse IL-10 i.p., or anti-TNF antibodies
i.p., 30 minutes before LPS administration. Mice are monitored for
death for 72 hours following the LPS injection.
[0151] (e) Evaluation of a Compound of Interest in a Rodent Model
of Asthma/Allergic Lung Inflammation.
[0152] CCR6 compounds of the invention can be assessed in a murine
model of allergic asthma. Asthma is induced in 8-10 week old BALB/c
mice by sensitizing mice with OVA in Alum adjuvant on days 0 and
10. On day 20 mice are challenged with OVA in PBS intranasally to
elicit airway inflammation. Groups of mice are either treated with
vehicle, or increasing doses of a compound of the invention
starting on day 20 and lasting until day 23. Animals are
subsequently analyzed at day 23 after the intranasal OVA challenge
for cellular infiltrates in bronchoalveolar lavage (BAL). Mice
treated with a compound of the invention will display significantly
reduced BAL leukocyte numbers relative to vehicle treated mice.
[0153] (f) Evaluation of a Compound of Interest in a Mouse Model of
Rheumatoid Arthritis.
[0154] This example describes a procedure to evaluate the efficacy
of CCR6 antagonists for treatment of rheumatoid arthritis. An
animal model of rheumatoid arthritis was induced in rodents by
injecting them with type II collagen in selected adjuvants. Three
series of rodent groups consisting of 15 genetically-susceptible
mice or rats per group were injected sub-cutaneously or
intra-dermally with type II collagen emulsified in Complete
Freund's Adjuvant at days 0 and 21. One series of rodents
additionally received PBS and Tween 0.5% i.p. at the initial
sensitization and at different dosing schedules thereafter. A
second series consists of groups of rodents received different
doses of the CCR6 antagonist given either intra-peritoneally,
intra-venously, sub-cutaneously, intramuscularly, orally, or via
any other mode of administration at the initial sensitization, and
at different dosing schedules thereafter. A third series of
rodents, serving as positive control, may consist of groups treated
with either mouse IL-10 i.p., or anti-TNF antibodies i.p. at the
initial sensitization, and at different dosing schedules
thereafter. Animals were monitored from weeks 3 till 8 for the
development of swollen joints or paws, and graded on a standard
disease severity scale. Disease severity was confirmed by
histological analysis of joints. Animals treated with compound
1.061 of the invention displayed significantly improved scores
following treatment.
[0155] (g) Evaluation of a Compound of Interest in a Mouse Model of
SLE.
[0156] This example describes a procedure to evaluate efficacy of
CCR6 antagonists for treatment of Systemic Lupus Erythematosus
(SLE). Female NZB/W FI mice spontaneously develop an SLE-like
pathology commencing at 6 months of age that is characterized by
proteinuria, serum autoantibodies, glomerulonephritis, and
eventually death. Three series of NZB/W FI mouse groups comprising
20 mice per group are tested for efficacy of CCR6 antagonist as
follows: One series of mice additionally receives phosphate
buffered saline (PBS) and Tween 0.5% i.p. soon after weaning, and
thereafter at varying dosing schedules. A second series consists of
groups of mice receiving different doses of the CCR6 antagonist
given either intra-peritoneally, intra-venously, sub-cutaneously,
intramuscularly, orally, or via any other mode of administration
soon after weaning, and thereafter at varying dosing schedules. A
third series of mice, serving as positive control, consists of
groups treated with anti-IL10 antibodies given soon after weaning,
and thereafter at varying dosing schedules. Disease development is
monitored in terms of eventual mortality, kidney histology, serum
autoantibody levels, and proteinuria.
[0157] (h) Evaluation of a Compound of Interest in a Mouse Model of
Malignancy.
[0158] This example describes a procedure to evaluate efficacy of
CCR6 antagonists for treatment of malignancy. Normal mouse strains
can be transplanted with a variety of well-characterized mouse
tumor lines, including a mouse thymoma EL4 which has been
transfected with OVA to allow easy evaluation of tumor specific
antigen responses following vaccination with OVA. Three series of
mouse groups from any of these tumor models are tested for CCR6
antagonist efficacy as follows: One series of mice additionally
receives PBS and Tween 0.5% i.p. soon after tumor transplant, and
thereafter at varying dosing schedules. A second series consists of
groups of mice receiving different doses of the CCR6 antagonist
given either intra-peritoneally, intra-venously, sub-cutaneously,
intramuscularly, orally, or via any other mode of administration
soon after tumor transplant, and thereafter at varying dosing
schedules. A third series of mice, serving as positive control,
consists of groups treated with either anti-IL17 antibodies,
anti-IFNg antibodies, given i.p. soon after tumor transplant, and
thereafter at varying dosing schedules. Efficacy is monitored via
tumor growth versus regression. In the case of the OVA-transfected
EL4 thymoma model, cytolytic OVA-specific responses can be measured
by stimulating draining lymph node cells with OVA in vitro, and
measuring antigen-specific cytotoxicity at 72 hours. Analysis can
be performed on eg. tumor mass, IL-17 levels or infiltration of
regulatory T cells and treatment with a compound of the invention
would be expected to produce a beneficial effect in this model.
[0159] (i) Evaluation of a Compound of Interest in a Mouse
Carcinoma Model.
[0160] The mouse RENCA tumor model accurately mimics the
progression of human adult renal cell carcinoma specifically with
reference to spontaneous metastasis to lungs and serves as a model
for solid tumors. Balb/c 6-8 week old female mice are inoculated
with approximately 5e5 RENCA cells (mouse renal adenocarcinoma;
ATCC cat# CRL-2947) under the kidney capsule and kidney tumor
growth is observed over 22 days, with lung metastasis observed as
early as day 15. Animals are dosed with either vehicle or a
compound of the invention eg daily subcutaneously, from the time of
tumor implantation to monitor effects on primary growth, or at a
later time (eg day 7) to monitor the compound effect on metastasis.
Primary tumor areas are measured twice a week using mechanical
calipers. Tumor volumes are calculated by the formula v=pab2/6,
where a is the longest diameter and b is the next longest diameter
perpendicular to a. A reduction in tumor volume or incidence of
metastasis indicates efficacy of compound in this indication.
[0161] (j) Evaluation of a Compound of Interest in a Mouse Model of
IBD.
[0162] This example describes a procedure to evaluate the efficacy
of CCR6 antagonists in Inflammatory Bowel Disease (IBD). Several
mouse models of IBD (including Crohn's Disease and Ulcerative
Colitis) have been developed. Some of these are spontaneous models
occurring in genetically engineered transgenic mice that have been
depleted of certain cytokine genes (e.g. IL-I0, or IL-2). Another
mouse model of IBD is obtained by transferring highly purified
populations of CD4+T lymphocytes bearing a particular surface
marker phenotype (namely CD45 RB hi) into SCID mice. Three series
of mouse groups from anyone of these models can be used to evaluate
CCR6 antagonist efficacy as follows. One group of mice additionally
receives PBS and Tween 0.5% i.p. soon after weaning in the case of
the spontaneous models in transgenic mice, or at time of cell
transfer into SCID mice and varying dosings thereafter for the cell
transfer model. A second series consists of groups of mice
receiving different doses of the CCR6 antagonist given either
intraperitoneally, intra-venously, sub-cutaneously,
intra-muscularly, orally, or via any other mode of administration
soon after weaning in the case of the spontaneous models in
transgenic mice, or at time of cell transfer into SCID mice and
varying dosings thereafter for the cell transfer model. A third
series of mice, serving as positive control, consists of groups
treated with antibodies to either IFNg, or TNF, or with cytokine
IL-10 soon after weaning in the case of the spontaneous models in
transgenic mice, or at time of cell transfer into SCID mice and
varying dosings thereafter for the cell transfer model. Mice are
evaluated for 6-8 weeks for disease development, monitored
initially via weight loss and/or prolapsed rectum, and eventually
by histological evaluation of the animals colon and intestinal
tract.
TABLE-US-00001 SEQ ID NO: 1 Human CCR6 mRNA transcript variant 1.
ACCESSION NM_004367 VERSION NM_004367.5 GI:150417991 1 agtgtatggg
tgaaggaggc agcagtgtgg ccggagagga gagctgggct gggagcacag 61
gaaggtcccc aggactctgt ggtcatcagt aagagagggc ccacgtgtat atgctggtga
121 acagaaatgt caaccttttc aaagtctgac atttaagaga aaaaactgtg
gctgttggtt 181 tgtggaacag acagctcctt ctttattgag tcacctctac
tttcctgcta ccgctgcctg 241 tgagctgaag gggctgaacc atacactcct
ttttctacaa ccagcttgca ttttttctgc 301 ccacaatgag cggggaatca
atgaatttca gcgatgtttt cgactccagt gaagattatt 361 ttgtgtcagt
caatacttca tattactcag ttgattctga gatgttactg tgctccttgc 421
aggaggtcag gcagttctcc aggctatttg taccgattgc ctactccttg atctgtgtct
481 ttggcctcct ggggaatatt ctggtggtga tcacctttgc tttttataag
aaggccaggt 541 ctatgacaga cgtctatctc ttgaacatgg ccattgcaga
catcctcttt gttcttactc 601 tcccattctg ggcagtgagt catgccaccg
gtgcgtgggt tttcagcaat gccacgtgca 661 agttgctaaa aggcatctat
gccatcaact ttaactgcgg gatgctgctc ctgacttgca 721 ttagcatgga
ccggtacatc gccattgtac aggcgactaa gtcattccgg ctccgatcca 781
gaacactacc gcgcagcaaa atcatctgcc ttgttgtgtg ggggctgtca gtcatcatct
841 ccagctcaac ttttgtcttc aaccaaaaat acaacaccca aggcagcgat
gtctgtgaac 901 ccaagtacca gactgtctcg gagcccatca ggtggaagct
gctgatgttg gggcttgagc 961 tactctttgg tttctttatc cctttgatgt
tcatgatatt ttgttacacg ttcattgtca 1021 aaaccttggt gcaagctcag
aattctaaaa ggcacaaagc catccgtgta atcatagctg 1081 tggtgcttgt
gtttctggct tgtcagattc ctcataacat ggtcctgctt gtgacggctg 1141
caaatttggg taaaatgaac cgatcctgcc agagcgaaaa gctaattggc tatacgaaaa
1201 ctgtcacaga agtcctggct ttcctgcact gctgcctgaa ccctgtgctc
tacgctttta 1261 ttgggcagaa gttcagaaac tactttctga agatcttgaa
ggacctgtgg tgtgtgagaa 1321 ggaagtacaa gtcctcaggc ttctcctgtg
ccgggaggta ctcagaaaac atttctcggc 1381 agaccagtga gaccgcagat
aacgacaatg cgtcgtcctt cactatgtga tagaaagctg 1441 agtctcccta
aggcatgtgt gaaacatact catagatgtt atgcaaaaaa aagtctatgg 1501
ccaggtatgc atggaaaatg tgggaattaa gcaaaatcaa gcaagcctct ctcctgcggg
1561 acttaacgtg ctcatgggct gtgtgatctc ttcagggtgg ggtggtctct
gataggtagc 1621 attttccagc actttgcaag gaatgttttg tagctctagg
gtatatatcc gcctggcatt 1681 tcacaaaaca gcctttggga aatgctgaat
taaagtgaat tgttgacaaa tgtaaacatt 1741 ttcagaaata ttcatgaagc
ggtcacagat cacagtgtct tttggttaca gcacaaaatg 1801 atggcagtgg
tttgaaaaac taaaacagaa aaaaaaatgg aagccaacac atcactcatt 1861
ttaggcaaat gtttaaacat ttttatctat cagaatgttt attgttgctg gttataagca
1921 gcaggattgg ccggctagtg tttcctctca tttccctttg atacagtcaa
caagcctgac 1981 cctgtaaaat ggaggtggaa agacaagctc aagtgttcac
aacctggaag tgcttcggga 2041 agaaggggac aatggcagaa caggtgttgg
tgacaattgt caccaattgg ataaagcagc 2101 tcaggttgta gtgggccatt
aggaaactgt cggtttgctt tgatttccct gggagctgtt 2161 ctctgtcgtg
agtgtctctt gtctaaacgt ccattaagct gagagtgcta tgaagacagg 2221
atctagaata atcttgctca cagctgtgct ctgagtgcct agcggagttc cagcaaacaa
2281 aatggactca agagagattt gattaatgaa tcgtaatgaa gttggggttt
attgtacagt 2341 ttaaaatgtt agatgttttt aattttttaa ataaatggaa
tacttttttt ttttttttaa 2401 agaaagcaac tttactgaga caatgtagaa
agaagttttg ttccgtttct ttaatgtggt 2461 tgaagagcaa tgtgtggctg
aagacttttg ttatgaggag ctgcagatta gctaggggac 2521 agctggaatt
atgctggctt ctgataatta ttttaaaggg gtctgaaatt tgtgatggaa 2581
tcagatttta acagctctct tcaatgacat agaaagttca tggaactcat gtttttaaag
2641 ggctatgtaa atatatgaac attagaaaaa tagcaacttg tgttacaaaa
atacaaacac 2701 atgttaggaa ggtactgtca tgggctaggc atggtggctc
acacctgtaa tcccagcatt 2761 ttgggaagct aagatgggtg gatcacttga
ggtcaggagt ttgagaccag cctggccaac 2821 atggcgaaac ccctctctac
taaaaataca aaaatttgcc aggcgtggtg gcgggtgcct 2881 gtaatcccag
ctacttggga ggctgaggca agagaatcgc ttgaacccag gaggcagagg 2941
ttgcagtgag ccgagatcgt gccattgcac tccagcctgg gtgacaaagc gagactccat
3001 ctcaaaaaaa aaaaaaaaaa aaaaggaaag aactgtcatg taaacatacc
aacatgttta 3061 aacctgacaa tggtgttatt tgaaacttta tattgttctt
gtaagcttta actatatctc 3121 tctttaaaat gcaaaataat gtcttaagat
tcaaagtctg tatttttaaa gcatggcttt 3181 ggctttgcaa aataaaaaat
gtgttttgta catgaa SEQ ID N: 2 Human CCR6 mRNA transcript variant 2.
ACCESSION NM_031409 VERSION NM_031409.3 GI:150417990 1 aactcacacg
gcctcttgca aacgttccca aatcttccca gtcggcttgc agagactcct 61
tgctcccagg agataaccag gtaaaggagt atgaaagttt gggtacaaac tcattgctgc
121 aaattgaaaa ccatgcaaag gctgtcttcc tctggggagt tcaatgcctc
tctttttctt 181 atcactttac cattggttgg actttgattc cagggatcct
acgattactc aataccctac 241 aggatataca tggttaacca tttgcatttg
ggcaaatagg cgttactttt caataggaag 301 tggcaatcca gaacttgctt
ttgggcaatt ctagtagctc accgcttttt tcttaatgac 361 tgctagaagc
tgcatcttat tgacagatgg tcatcacatt ggtgagctgg agtcatcaga 421
ttgtggggcc cggagtgagg ctgaagggag tggatcagag cactgcctga gagtcacctc
481 tactttcctg ctaccgctgc ctgtgagctg aaggggctga accatacact
cctttttcta 541 caaccagctt gcattttttc tgcccacaat gagcggggaa
tcaatgaatt tcagcgatgt 601 tttcgactcc agtgaagatt attttgtgtc
agtcaatact tcatattact cagttgattc 661 tgagatgtta ctgtgctcct
tgcaggaggt caggcagttc tccaggctat ttgtaccgat 721 tgcctactcc
ttgatctgtg tctttggcct cctggggaat attctggtgg tgatcacctt 781
tgctttttat aagaaggcca ggtctatgac agacgtctat ctcttgaaca tggccattgc
841 agacatcctc tttgttctta ctctcccatt ctgggcagtg agtcatgcca
ccggtgcgtg 901 ggttttcagc aatgccacgt gcaagttgct aaaaggcatc
tatgccatca actttaactg 961 cgggatgctg ctcctgactt gcattagcat
ggaccggtac atcgccattg tacaggcgac 1021 taagtcattc cggctccgat
ccagaacact accgcgcagc aaaatcatct gccttgttgt 1081 gtgggggctg
tcagtcatca tctccagctc aacttttgtc ttcaaccaaa aatacaacac 1141
ccaaggcagc gatgtctgtg aacccaagta ccagactgtc tcggagccca tcaggtggaa
1201 gctgctgatg ttggggcttg agctactctt tggtttcttt atccctttga
tgttcatgat 1261 attttgttac acgttcattg tcaaaacctt ggtgcaagct
cagaattcta aaaggcacaa 1321 agccatccgt gtaatcatag ctgtggtgct
tgtgtttctg gcttgtcaga ttcctcataa 1381 catggtcctg cttgtgacgg
ctgcaaattt gggtaaaatg aaccgatcct gccagagcga 1441 aaagctaatt
ggctatacga aaactgtcac agaagtcctg gctttcctgc actgctgcct 1501
gaaccctgtg ctctacgctt ttattgggca gaagttcaga aactactttc tgaagatctt
1561 gaaggacctg tggtgtgtga gaaggaagta caagtcctca ggcttctcct
gtgccgggag 1621 gtactcagaa aacatttctc ggcagaccag tgagaccgca
gataacgaca atgcgtcgtc 1681 cttcactatg tgatagaaag ctgagtctcc
ctaaggcatg tgtgaaacat actcatagat 1741 gttatgcaaa aaaaagtcta
tggccaggta tgcatggaaa atgtgggaat taagcaaaat 1801 caagcaagcc
tctctcctgc gggacttaac gtgctcatgg gctgtgtgat ctcttcaggg 1861
tggggtggtc tctgataggt agcattttcc agcactttgc aaggaatgtt ttgtagctct
1921 agggtatata tccgcctggc atttcacaaa acagcctttg ggaaatgctg
aattaaagtg 1981 aattgttgac aaatgtaaac attttcagaa atattcatga
agcggtcaca gatcacagtg 2041 tcttttggtt acagcacaaa atgatggcag
tggtttgaaa aactaaaaca gaaaaaaaaa 2101 tggaagccaa cacatcactc
attttaggca aatgtttaaa catttttatc tatcagaatg 2161 tttattgttg
ctggttataa gcagcaggat tggccggcta gtgtttcctc tcatttccct 2221
ttgatacagt caacaagcct gaccctgtaa aatggaggtg gaaagacaag ctcaagtgtt
2281 cacaacctgg aagtgcttcg ggaagaaggg gacaatggca gaacaggtgt
tggtgacaat 2341 tgtcaccaat tggataaagc agctcaggtt gtagtgggcc
attaggaaac tgtcggtttg 2401 ctttgatttc cctgggagct gttctctgtc
gtgagtgtct cttgtctaaa cgtccattaa 2461 gctgagagtg ctatgaagac
aggatctaga ataatcttgc tcacagctgt gctctgagtg 2521 cctagcggag
ttccagcaaa caaaatggac tcaagagaga tttgattaat gaatcgtaat 2581
gaagttgggg tttattgtac agtttaaaat gttagatgtt tttaattttt taaataaatg
2641 gaatactttt tttttttttt taaagaaagc aactttactg agacaatgta
gaaagaagtt 2701 ttgttccgtt tctttaatgt ggttgaagag caatgtgtgg
ctgaagactt ttgttatgag 2761 gagctgcaga ttagctaggg gacagctgga
attatgctgg cttctgataa ttattttaaa 2821 ggggtctgaa atttgtgatg
gaatcagatt ttaacagctc tcttcaatga catagaaagt 2881 tcatggaact
catgttttta aagggctatg taaatatatg aacattagaa aaatagcaac 2941
ttgtgttaca aaaatacaaa cacatgttag gaaggtactg tcatgggcta ggcatggtgg
3001 ctcacacctg taatcccagc attttgggaa gctaagatgg gtggatcact
tgaggtcagg 3061 agtttgagac cagcctggcc aacatggcga aacccctctc
tactaaaaat acaaaaattt 3121 gccaggcgtg gtggcgggtg cctgtaatcc
cagctacttg ggaggctgag gcaagagaat 3181 cgcttgaacc caggaggcag
aggttgcagt gagccgagat cgtgccattg cactccagcc 3241 tgggtgacaa
agcgagactc catctcaaaa aaaaaaaaaa aaaaaaagga aagaactgtc 3301
atgtaaacat accaacatgt ttaaacctga caatggtgtt atttgaaact ttatattgtt
3361 cttgtaagct ttaactatat ctctctttaa aatgcaaaat aatgtcttaa
gattcaaagt 3421 ctgtattttt aaagcatggc tttggctttg caaaataaaa
aatgtgtttt gtacatgaa SEQ ID NO: 3 Human CCR6 amino acid sequence
MSGESMNFSDVFDSSEDYFVSVNTSYYSVDSEMLLCSLQEVRQFSRLFVPIAYSLICVFG
LLGNILVVITFAFYKKARSMTDVYLLNMAIADILFVLTLPFWAVSHATGAWVFSNATCK
LLKGIYAINFNCGMLLLTCISMDRYIAIVQATKSFRLRSRTLPRSKIICLVVWGLSVIISSST
FVFNQKYNTQGSDVCEPKYQTVSEPIRWKLLMLGLELLFGFFIPLMFMIFCYTFIVKTLV
QAQNSKRHKAIRVIIAVVLVFLACQIPHNMVLLVTAANLGKMNRSCQSEKLIGYTKTVT
EVLAFLHCCLNPVLYAFIGQKFRNYFLKILKDLWCVRRKYKSSGFSCAGRYSENISRQTS
ETADNDNASSFTM
[0163] It is understood that the examples and embodiments described
herein are for illustrative purposes only and that various
modifications or changes in light thereof will be suggested to
persons skilled in the art and are to be included within the spirit
and purview of this application and scope of the appended
claims.
[0164] All publications, patents, and patent applications cited
herein are hereby incorporated by reference in their entirety for
all purposes.
Sequence CWU 1
1
313216DNAHomo sapienschemokine (C-C motif) receptor 6 (CCR6, C-C
CKR-6), transcript variant 1, chemokine receptor-like 3 (CKR-L3),
G-protein-coupled receptor 29 (GPR29), seven-transmembrane
receptor, lymphocyte, 22 (STRL22), LARC receptor, CD196, CMKBR6,
DCR2, DRY6, GPRCY4 1agtgtatggg tgaaggaggc agcagtgtgg ccggagagga
gagctgggct gggagcacag 60gaaggtcccc aggactctgt ggtcatcagt aagagagggc
ccacgtgtat atgctggtga 120acagaaatgt caaccttttc aaagtctgac
atttaagaga aaaaactgtg gctgttggtt 180tgtggaacag acagctcctt
ctttattgag tcacctctac tttcctgcta ccgctgcctg 240tgagctgaag
gggctgaacc atacactcct ttttctacaa ccagcttgca ttttttctgc
300ccacaatgag cggggaatca atgaatttca gcgatgtttt cgactccagt
gaagattatt 360ttgtgtcagt caatacttca tattactcag ttgattctga
gatgttactg tgctccttgc 420aggaggtcag gcagttctcc aggctatttg
taccgattgc ctactccttg atctgtgtct 480ttggcctcct ggggaatatt
ctggtggtga tcacctttgc tttttataag aaggccaggt 540ctatgacaga
cgtctatctc ttgaacatgg ccattgcaga catcctcttt gttcttactc
600tcccattctg ggcagtgagt catgccaccg gtgcgtgggt tttcagcaat
gccacgtgca 660agttgctaaa aggcatctat gccatcaact ttaactgcgg
gatgctgctc ctgacttgca 720ttagcatgga ccggtacatc gccattgtac
aggcgactaa gtcattccgg ctccgatcca 780gaacactacc gcgcagcaaa
atcatctgcc ttgttgtgtg ggggctgtca gtcatcatct 840ccagctcaac
ttttgtcttc aaccaaaaat acaacaccca aggcagcgat gtctgtgaac
900ccaagtacca gactgtctcg gagcccatca ggtggaagct gctgatgttg
gggcttgagc 960tactctttgg tttctttatc cctttgatgt tcatgatatt
ttgttacacg ttcattgtca 1020aaaccttggt gcaagctcag aattctaaaa
ggcacaaagc catccgtgta atcatagctg 1080tggtgcttgt gtttctggct
tgtcagattc ctcataacat ggtcctgctt gtgacggctg 1140caaatttggg
taaaatgaac cgatcctgcc agagcgaaaa gctaattggc tatacgaaaa
1200ctgtcacaga agtcctggct ttcctgcact gctgcctgaa ccctgtgctc
tacgctttta 1260ttgggcagaa gttcagaaac tactttctga agatcttgaa
ggacctgtgg tgtgtgagaa 1320ggaagtacaa gtcctcaggc ttctcctgtg
ccgggaggta ctcagaaaac atttctcggc 1380agaccagtga gaccgcagat
aacgacaatg cgtcgtcctt cactatgtga tagaaagctg 1440agtctcccta
aggcatgtgt gaaacatact catagatgtt atgcaaaaaa aagtctatgg
1500ccaggtatgc atggaaaatg tgggaattaa gcaaaatcaa gcaagcctct
ctcctgcggg 1560acttaacgtg ctcatgggct gtgtgatctc ttcagggtgg
ggtggtctct gataggtagc 1620attttccagc actttgcaag gaatgttttg
tagctctagg gtatatatcc gcctggcatt 1680tcacaaaaca gcctttggga
aatgctgaat taaagtgaat tgttgacaaa tgtaaacatt 1740ttcagaaata
ttcatgaagc ggtcacagat cacagtgtct tttggttaca gcacaaaatg
1800atggcagtgg tttgaaaaac taaaacagaa aaaaaaatgg aagccaacac
atcactcatt 1860ttaggcaaat gtttaaacat ttttatctat cagaatgttt
attgttgctg gttataagca 1920gcaggattgg ccggctagtg tttcctctca
tttccctttg atacagtcaa caagcctgac 1980cctgtaaaat ggaggtggaa
agacaagctc aagtgttcac aacctggaag tgcttcggga 2040agaaggggac
aatggcagaa caggtgttgg tgacaattgt caccaattgg ataaagcagc
2100tcaggttgta gtgggccatt aggaaactgt cggtttgctt tgatttccct
gggagctgtt 2160ctctgtcgtg agtgtctctt gtctaaacgt ccattaagct
gagagtgcta tgaagacagg 2220atctagaata atcttgctca cagctgtgct
ctgagtgcct agcggagttc cagcaaacaa 2280aatggactca agagagattt
gattaatgaa tcgtaatgaa gttggggttt attgtacagt 2340ttaaaatgtt
agatgttttt aattttttaa ataaatggaa tacttttttt ttttttttaa
2400agaaagcaac tttactgaga caatgtagaa agaagttttg ttccgtttct
ttaatgtggt 2460tgaagagcaa tgtgtggctg aagacttttg ttatgaggag
ctgcagatta gctaggggac 2520agctggaatt atgctggctt ctgataatta
ttttaaaggg gtctgaaatt tgtgatggaa 2580tcagatttta acagctctct
tcaatgacat agaaagttca tggaactcat gtttttaaag 2640ggctatgtaa
atatatgaac attagaaaaa tagcaacttg tgttacaaaa atacaaacac
2700atgttaggaa ggtactgtca tgggctaggc atggtggctc acacctgtaa
tcccagcatt 2760ttgggaagct aagatgggtg gatcacttga ggtcaggagt
ttgagaccag cctggccaac 2820atggcgaaac ccctctctac taaaaataca
aaaatttgcc aggcgtggtg gcgggtgcct 2880gtaatcccag ctacttggga
ggctgaggca agagaatcgc ttgaacccag gaggcagagg 2940ttgcagtgag
ccgagatcgt gccattgcac tccagcctgg gtgacaaagc gagactccat
3000ctcaaaaaaa aaaaaaaaaa aaaaggaaag aactgtcatg taaacatacc
aacatgttta 3060aacctgacaa tggtgttatt tgaaacttta tattgttctt
gtaagcttta actatatctc 3120tctttaaaat gcaaaataat gtcttaagat
tcaaagtctg tatttttaaa gcatggcttt 3180ggctttgcaa aataaaaaat
gtgttttgta catgaa 321623479DNAHomo sapienschemokine (C-C motif)
receptor 6 (CCR6, C-C CKR-6), transcript variant 2, chemokine
receptor-like 3 (CKR-L3), G-protein-coupled receptor 29 (GPR29),
seven-transmembrane receptor, lymphocyte, 22 (STRL22), LARC
receptor, CD196, CMKBR6, DCR2, DRY6, GPRCY4 2aactcacacg gcctcttgca
aacgttccca aatcttccca gtcggcttgc agagactcct 60tgctcccagg agataaccag
gtaaaggagt atgaaagttt gggtacaaac tcattgctgc 120aaattgaaaa
ccatgcaaag gctgtcttcc tctggggagt tcaatgcctc tctttttctt
180atcactttac cattggttgg actttgattc cagggatcct acgattactc
aataccctac 240aggatataca tggttaacca tttgcatttg ggcaaatagg
cgttactttt caataggaag 300tggcaatcca gaacttgctt ttgggcaatt
ctagtagctc accgcttttt tcttaatgac 360tgctagaagc tgcatcttat
tgacagatgg tcatcacatt ggtgagctgg agtcatcaga 420ttgtggggcc
cggagtgagg ctgaagggag tggatcagag cactgcctga gagtcacctc
480tactttcctg ctaccgctgc ctgtgagctg aaggggctga accatacact
cctttttcta 540caaccagctt gcattttttc tgcccacaat gagcggggaa
tcaatgaatt tcagcgatgt 600tttcgactcc agtgaagatt attttgtgtc
agtcaatact tcatattact cagttgattc 660tgagatgtta ctgtgctcct
tgcaggaggt caggcagttc tccaggctat ttgtaccgat 720tgcctactcc
ttgatctgtg tctttggcct cctggggaat attctggtgg tgatcacctt
780tgctttttat aagaaggcca ggtctatgac agacgtctat ctcttgaaca
tggccattgc 840agacatcctc tttgttctta ctctcccatt ctgggcagtg
agtcatgcca ccggtgcgtg 900ggttttcagc aatgccacgt gcaagttgct
aaaaggcatc tatgccatca actttaactg 960cgggatgctg ctcctgactt
gcattagcat ggaccggtac atcgccattg tacaggcgac 1020taagtcattc
cggctccgat ccagaacact accgcgcagc aaaatcatct gccttgttgt
1080gtgggggctg tcagtcatca tctccagctc aacttttgtc ttcaaccaaa
aatacaacac 1140ccaaggcagc gatgtctgtg aacccaagta ccagactgtc
tcggagccca tcaggtggaa 1200gctgctgatg ttggggcttg agctactctt
tggtttcttt atccctttga tgttcatgat 1260attttgttac acgttcattg
tcaaaacctt ggtgcaagct cagaattcta aaaggcacaa 1320agccatccgt
gtaatcatag ctgtggtgct tgtgtttctg gcttgtcaga ttcctcataa
1380catggtcctg cttgtgacgg ctgcaaattt gggtaaaatg aaccgatcct
gccagagcga 1440aaagctaatt ggctatacga aaactgtcac agaagtcctg
gctttcctgc actgctgcct 1500gaaccctgtg ctctacgctt ttattgggca
gaagttcaga aactactttc tgaagatctt 1560gaaggacctg tggtgtgtga
gaaggaagta caagtcctca ggcttctcct gtgccgggag 1620gtactcagaa
aacatttctc ggcagaccag tgagaccgca gataacgaca atgcgtcgtc
1680cttcactatg tgatagaaag ctgagtctcc ctaaggcatg tgtgaaacat
actcatagat 1740gttatgcaaa aaaaagtcta tggccaggta tgcatggaaa
atgtgggaat taagcaaaat 1800caagcaagcc tctctcctgc gggacttaac
gtgctcatgg gctgtgtgat ctcttcaggg 1860tggggtggtc tctgataggt
agcattttcc agcactttgc aaggaatgtt ttgtagctct 1920agggtatata
tccgcctggc atttcacaaa acagcctttg ggaaatgctg aattaaagtg
1980aattgttgac aaatgtaaac attttcagaa atattcatga agcggtcaca
gatcacagtg 2040tcttttggtt acagcacaaa atgatggcag tggtttgaaa
aactaaaaca gaaaaaaaaa 2100tggaagccaa cacatcactc attttaggca
aatgtttaaa catttttatc tatcagaatg 2160tttattgttg ctggttataa
gcagcaggat tggccggcta gtgtttcctc tcatttccct 2220ttgatacagt
caacaagcct gaccctgtaa aatggaggtg gaaagacaag ctcaagtgtt
2280cacaacctgg aagtgcttcg ggaagaaggg gacaatggca gaacaggtgt
tggtgacaat 2340tgtcaccaat tggataaagc agctcaggtt gtagtgggcc
attaggaaac tgtcggtttg 2400ctttgatttc cctgggagct gttctctgtc
gtgagtgtct cttgtctaaa cgtccattaa 2460gctgagagtg ctatgaagac
aggatctaga ataatcttgc tcacagctgt gctctgagtg 2520cctagcggag
ttccagcaaa caaaatggac tcaagagaga tttgattaat gaatcgtaat
2580gaagttgggg tttattgtac agtttaaaat gttagatgtt tttaattttt
taaataaatg 2640gaatactttt tttttttttt taaagaaagc aactttactg
agacaatgta gaaagaagtt 2700ttgttccgtt tctttaatgt ggttgaagag
caatgtgtgg ctgaagactt ttgttatgag 2760gagctgcaga ttagctaggg
gacagctgga attatgctgg cttctgataa ttattttaaa 2820ggggtctgaa
atttgtgatg gaatcagatt ttaacagctc tcttcaatga catagaaagt
2880tcatggaact catgttttta aagggctatg taaatatatg aacattagaa
aaatagcaac 2940ttgtgttaca aaaatacaaa cacatgttag gaaggtactg
tcatgggcta ggcatggtgg 3000ctcacacctg taatcccagc attttgggaa
gctaagatgg gtggatcact tgaggtcagg 3060agtttgagac cagcctggcc
aacatggcga aacccctctc tactaaaaat acaaaaattt 3120gccaggcgtg
gtggcgggtg cctgtaatcc cagctacttg ggaggctgag gcaagagaat
3180cgcttgaacc caggaggcag aggttgcagt gagccgagat cgtgccattg
cactccagcc 3240tgggtgacaa agcgagactc catctcaaaa aaaaaaaaaa
aaaaaaagga aagaactgtc 3300atgtaaacat accaacatgt ttaaacctga
caatggtgtt atttgaaact ttatattgtt 3360cttgtaagct ttaactatat
ctctctttaa aatgcaaaat aatgtcttaa gattcaaagt 3420ctgtattttt
aaagcatggc tttggctttg caaaataaaa aatgtgtttt gtacatgaa
34793374PRTHomo sapienschemokine (C-C motif) receptor 6 (CCR6, C-C
CKR-6), chemokine receptor-like 3 (CKR-L3), G-protein-coupled
receptor 29 (GPR29), seven-transmembrane receptor, lymphocyte, 22
(STRL22), LARC receptor, CD196, CMKBR6, DCR2, DRY6, GPRCY4 3Met Ser
Gly Glu Ser Met Asn Phe Ser Asp Val Phe Asp Ser Ser Glu1 5 10 15Asp
Tyr Phe Val Ser Val Asn Thr Ser Tyr Tyr Ser Val Asp Ser Glu 20 25
30Met Leu Leu Cys Ser Leu Gln Glu Val Arg Gln Phe Ser Arg Leu Phe
35 40 45Val Pro Ile Ala Tyr Ser Leu Ile Cys Val Phe Gly Leu Leu Gly
Asn 50 55 60Ile Leu Val Val Ile Thr Phe Ala Phe Tyr Lys Lys Ala Arg
Ser Met65 70 75 80Thr Asp Val Tyr Leu Leu Asn Met Ala Ile Ala Asp
Ile Leu Phe Val 85 90 95Leu Thr Leu Pro Phe Trp Ala Val Ser His Ala
Thr Gly Ala Trp Val 100 105 110Phe Ser Asn Ala Thr Cys Lys Leu Leu
Lys Gly Ile Tyr Ala Ile Asn 115 120 125Phe Asn Cys Gly Met Leu Leu
Leu Thr Cys Ile Ser Met Asp Arg Tyr 130 135 140Ile Ala Ile Val Gln
Ala Thr Lys Ser Phe Arg Leu Arg Ser Arg Thr145 150 155 160Leu Pro
Arg Ser Lys Ile Ile Cys Leu Val Val Trp Gly Leu Ser Val 165 170
175Ile Ile Ser Ser Ser Thr Phe Val Phe Asn Gln Lys Tyr Asn Thr Gln
180 185 190Gly Ser Asp Val Cys Glu Pro Lys Tyr Gln Thr Val Ser Glu
Pro Ile 195 200 205Arg Trp Lys Leu Leu Met Leu Gly Leu Glu Leu Leu
Phe Gly Phe Phe 210 215 220Ile Pro Leu Met Phe Met Ile Phe Cys Tyr
Thr Phe Ile Val Lys Thr225 230 235 240Leu Val Gln Ala Gln Asn Ser
Lys Arg His Lys Ala Ile Arg Val Ile 245 250 255Ile Ala Val Val Leu
Val Phe Leu Ala Cys Gln Ile Pro His Asn Met 260 265 270Val Leu Leu
Val Thr Ala Ala Asn Leu Gly Lys Met Asn Arg Ser Cys 275 280 285Gln
Ser Glu Lys Leu Ile Gly Tyr Thr Lys Thr Val Thr Glu Val Leu 290 295
300Ala Phe Leu His Cys Cys Leu Asn Pro Val Leu Tyr Ala Phe Ile
Gly305 310 315 320Gln Lys Phe Arg Asn Tyr Phe Leu Lys Ile Leu Lys
Asp Leu Trp Cys 325 330 335Val Arg Arg Lys Tyr Lys Ser Ser Gly Phe
Ser Cys Ala Gly Arg Tyr 340 345 350Ser Glu Asn Ile Ser Arg Gln Thr
Ser Glu Thr Ala Asp Asn Asp Asn 355 360 365Ala Ser Ser Phe Thr Met
370
* * * * *